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Abstract 
 
Herpes simplex virus (HSV) infection of the eye results in chronic 
immunopathological response in corneal stroma orchestrated by CD4 T cells. Due to its 
neurotrophic nature, HSV can also invade brain and leads to deadly encephalitis. HSV 
infection of the eyes leads to corneal neovascularization (CV), which is an important step 
in the pathogenesis of herpetic stromal keratitis (HSK), an important cause of human 
blindness. This study was undertaken to investigate the contribution of miRNAs and 
Robo4 signaling in HSK. The role of miR-132 and miR-155 was evaluated. In the first 
chapter, we review literature regarding the contribution of miRNAs in several human 
diseases and speculate about the role of those miRNAs in herpes viral latency and HSK. 
We also discuss involvement of Robo4 signaling in the context of pathological 
angiogenesis. 
 In the second chapter, we show that HSV infection of the eyes of mice leads to 
appearance of Robo4+ blood vessel endothelial cells in corneas but levels of Slit2 (a 
ligand for Robo4 receptor) were minimal. The provision of exogenous Slit2 protein 
reduced CV following HSV infection.  
In the third chapter, we report the role of miR-132 in angiogenesis following 
ocular HSV infection. We observed VEGF and IL-17 driven upregulation of miR-132 
during HSK. miR-132 was shown to augment VEGF induced angiogenic responses and 
blockade of miR-132 using antagomir nanoparticles reduced pathological angiogenesis in 
eyes after HSV infection. 
 In the fourth chapter, we analyzed the involvement of miR-155 after ocular 
infection with HSV. The mice unable to produce miR-155 were found to be highly 
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susceptible to encephalitis after HSV infection with the majority of mice dyeing by day 9. 
We further show that virus replication in brain was responsible for death in miR-155 null 
mice. When T cell responses were measured, miR-155 knockout animals demonstrated 
attenuated CD4 and virus specific CD8 T cell immunity. Additionally, we also evaluated 
the role of miR-155 in HSK. miR-155KO survivors from herpes simplex encephalitis 
were relatively resistant to HSK. In conclusion, we demonstrated that the miR-155 is a 
regulator of herpes simplex encephalitis but it promotes inflammation during HSK.  
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Background and overview are modified from a review accepted in IOVS by Sachin 
Mulik, '!(()*+)#,-".)*/,",0(".,--1"2"345+*6 
Mulik S, Bhela S, Rouse BT. Potential function of miRNAs in herpetic stromal keratitis. 
Invest Ophthalmol Vis Sci. 2013: in press. Copyrights held by ARVO. 
Potential function of miRNAs in herpetic stromal keratitis 
 
Abstract 
MicroRNAs (miRNAs), the newly discovered regulators of gene expression, act 
by promoting degradation of mRNA and by inhibiting protein expression. Dysregulation 
of miRNA expression has been noted in an expanding number of diseases and in some 
instances manipulating miRNA expression holds promise as a new form of therapy. 
Herpetic stromal keratitis (HSK) is an important vision impairing lesion and currently 
any role that miRNA dysregulation plays during its pathogenesis is only just beginning to 
be investigated. In this review we discuss the likely participation of specific miRNAs 
during HSK and discuss the prospect of modulating their expression as a means of 
therapy. 
 
Introduction 
The discovery of a novel mechanism of gene regulation by miRNAs in nematodes 
by Ambros and colleagues
1
 stimulated an intense search for similar regulatory 
mechanisms in mammalian cells. The search has yielded abundantly with at least 800 
different miRNA species identified with many of them dysregulated in metabolic 
pathways that result in neoplasia, autoimmunity and an expanding number of other 
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human diseases. In several instances either restoring miRNA levels or blocking their 
activity represents a valuable means of therapy. Currently our understanding of miRNA 
involvement during the pathogenesis of stromal keratitis caused by herpes simplex virus 
(HSV) is very much in its infancy. This topic is discussed along with a speculative 
assessment of the prospects of manipulating selected species of miRNAs as a therapeutic 
maneuver that could reach the clinic.  
 
What are microRNAs? 
 miRNA’s are genome encoded small, single stranded RNAs that post 
transcriptionally down regulate gene expression either by degradation or translation 
repression of the target mRNA. All canonical miRNA biogenesis process begins in the 
nucleus where stem loops in the pri-miRNA are recognized by the enzyme Drosha and its 
cofactor DGCR8, which cause nuclear cleavage to result in 60 nt precursor called pre-
miRNA (figure 1.1). The pre-miRNA is exported to the cytoplasm with the help of 
Exportin 5 and further processed with the help of another enzyme, Dicer. The Dicer 
reduces the RNA size further to about 21 nt and also helps in the loading of the miRNA 
single strand into the miRNA-induced silencing complex (miRISC). The miRNA guides 
the miRISC to the target mRNA and the degree of complementarity between the miRNA 
and the target mRNA determines the fate of the mRNA. If the two have high 
complementary sequences the target mRNA is degraded by miRISC consisting of 
Argonaut proteins. If there is only partial complimentary sequences between the miRNA 
and the target mRNA, this would result in transcriptional repression by several miRISC 
complexes bound to different sites on the target mRNA. Accordingly, miRNAs usually 
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act to fine tune gene expression rather than to act as on/off switches. It is important to 
note that not all cellular miRNAs use the canonical pathways, there are few other 
mechanisms used by cells to generate functional miRNAs which have been reviewed in 
detail by others
2
 and theses are not discussed herein. 
Most miRNA genes are expressed under control of their own promoters and 
regulatory sequences and act alone in gene regulation. However, others are arranged in 
clusters and are expressed and function together (for example the miR-19-92 cluster). 
The impact of miRNA expression during human and animal diseases has become known 
from a variety of experimental approaches. These have included measuring the 
consequences of gene knockout or over-expression, as can be done in experimental 
rodent studies. Alternatively, miRNA expression can be reduced in vivo by antagomir 
(miRNA inhibitory sequences) nanoparticle approaches, or be enhanced either by 
administrating miRNA in nanoparticles, or by causing their biosynthesis using vectors 
encoding miRNAs. 
 
Herpetic Stromal keratitis: Role of Robo4 signaling and microRNAs 
  Infection with HSV generally leads to lesions on surface structures that include 
the cornea of the eye. The infection can be acute, involving largely the epithelium and 
resolve quite quickly, especially if treated with antivirals. Some cases, however, result in 
chronic lesions that involve the corneal stroma and these impair vision and can even 
result in blindness. HSK lesions in humans are commonly the consequence of one or 
more episodes of HSV reactivation from latency
3
. The tissue damage that occurs in HSK 
is thought to result in large part from the host inflammatory reaction and residual scarring 
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set off by the infection. The strongest case that tissue damage in HSK represents an 
immunopathological response to infection comes from animal studies, particularly the 
mouse
4
. Such studies have identified several essential steps in lesion pathogenesis some 
or all of which could be subject to regulation by yet to be identified miRNA species. 
Several miRNAs are expressed by healthy mouse corneas under physiological 
conditions
5
. Among these miR-132, miR-182 and miR-1 are expressed at low levels, 
miR-146b shows intermediate expression while miR-21, miR-23b and miR-24 are 
expressed at high levels in corneas. However, their contribution in modulating critical 
events in corneal immunopathology during HSK remains largely unknown. The details of 
HSK pathogenesis have received some recent reviews
6, 7
 and herein we mention only a 
few essential points. Firstly, the inciting HSV infection in humans usually derives from a 
breakdown of latent infection in the trigeminal ganglia, which is caused by exposure to a 
variety of stressful stimuli. Accordingly, understanding how to sustain latency and 
prevent reactivation is an important issue, and miRNAs could influence these events.  
Early steps following HSV infection largely represent the response of innate 
defenses and these may be sufficient to control virus before significant inflammatory 
lesions occur. The overt HSK lesions appear to be inflammatory reactions orchestrated 
mainly by T cells, particularly CD4 T cells of the Th-1 subset
8
. However, the principal 
tissue damage and resultant corneal scarring is mainly attributed to inflammatory 
products derived from nonlymphoid inflammatory cells such as neutrophils and 
macrophages
9, 10
. Finally, the onset and extent of HSK lesions is influenced by the 
neovascularization that occurs in the normally transparent avascular cornea
11
. 
Understanding how to limit and resolve corneal neovascularization (CV) is an important 
 :"
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therapeutic objective. As we discuss, the CV process is subject to control by one or more 
species of miRNAs with a recent publication implicating the relevance of miR-132
12
. 
 
miRNAs and Latency 
The hallmark of all herpes virus infections is their ability to persist indefinitely in 
the body in a state called latency. In the case of HSV, latency is maintained in neuronal 
tissue, which with ocular infection means the trigeminal ganglion. During latency, the 
virus produces no proteins so the agent may be invisible to the adaptive immune system. 
Unfortunately, latency terminates in occasional neurons, which is probably a continual 
process
13
. Productive replication occurs in such neurons and virus disseminates to 
peripheral sites where it can cause recurrent lesions. It is conceivable that the regulatory 
effects of miRNAs could influence the initiation, maintenance and breakdown of latency, 
as well as whether or not the productive infection is sufficient to induce lesions. All of 
these points here have yet to be firmly established.  
With regard to the establishment of latency, HSV itself encodes a number of 
miRNAs and these could influence the extent to which either latent or productive 
infection of neurons occurs
14
. For example, the transcript expressed uniquely during 
latency, LAT, serves as a primary miRNA precursor that encodes four distinct miRNAs 
in HSV infected cells. One of these miRNAs, mir-H2-3p, can influence the expression of 
the viral immediate early gene ICP0
14
. Another miRNA, miR-H6, which lies upstream of 
the LAT promoter, modulates the expression of ICP4
14
. These observations came from in 
vitro transfection assays, but if, as is likely, the same effect occurs in vivo, the miRNA 
regulation could be highly relevant since both ICP4 and ICP0 proteins are involved in the 
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initial phases of productive replication following primary and recurrent infections
15, 16
 
Conceivably, virus encoded miRNAs could influence the amount of ICP4 and ICP0 
expression in a latently infected neuron and this might determine if the productive cycle 
is initiated. However, viral encoded miRNA regulation of HSV latency in vivo remains 
an unresolved and debatable issue
17
, that merits more investigation.  
Perhaps more amenable to therapeutic manipulation to influence latency will be to 
identify any host encoded miRNAs that are responsible for maintaining latency and 
which may lose this function in response to circumstances that cause reactivation. Such 
circumstances include changes in hormone levels caused by stress or other events, 
changes in immune status and exposure to UV irradiation being among the most 
investigated. The herpetic recurrences that follow stressful experiences could be mediated 
by changes in glucocorticoid levels and many studies have documented that 
glucocorticoids can influence miRNA expression
18
. For example, glucocorticoids can 
cause upregulation of the miRNA clusters miR-15/16 or miR-233
19
, but as yet none have 
been related to latency. It would be of interest to determine if any changes of these 
miRNA clusters precede the onset of viral reactivation. Additionally, glucocorticoids may 
also influence gene expression changes by histone modifications, an event also 
implicated in the maintenance of latency
20
. The glucocorticoid binding to cytoplasmic 
glucocorticoid receptors triggers events that lead to induction of some anti-inflammatory 
genes. These effects occur in part via recruitment of histone modifying transcriptional 
coactivators and other cofactors to glucocorticoid responsive elements in the responsive 
genes
21
. Moreover, glucocorticoid signaling can recruit histone deacetylases to the NFkB 
complex and inhibit inflammatory gene expression
22
. These epigenetic events influenced 
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by glucocorticoids could be caused by miRNA expression changes. For example, miR-
449 and miR-1 are involved in regulating the activity of histone acetylation
23, 24
. It 
remains to be seen whether glucocorticoids may promote virus reactivation via changing 
the levels of histone modification associated miRNAs (fig 1.2). 
Another event that often causes the onset of recurrent herpes lesions is exposure 
to excessive sunlight, such as sunburn. Exposure to UV light can also trigger reactivation 
of HSV in a keratitis model in mice
25
.  How UV irradiation or sunburn induces herpes 
virus reactivation remains unclear, but recent reports indicate a potential role for miRNAs 
in this process. For instance, the knockdown of Ago2 and Dicer, essential components of 
the miRNA processing pathway, reduces survival of HELA cells exposed to UV 
radiation
26
. This could mean that miRNAs play a critical role in UV induced cell cycle 
events and apoptosis. Perhaps of more relevance, dysregulation in miR-21, miR-203, 
miR-205, miR-24, let-7a and miR-376b is observed in murine epidermal tissue and 
human kertatinocytes upon UV exposure
27
. At least two of these, miR-21 and miR-24
28, 
29
, can influence CD8 T cell functionality which, as mentioned subsequently, may 
participate in the maintenance of latency
30, 31
 (fig 1.2). 
Another well studied situation that may influence the stability and breakdown of 
latency is immune status. For example, immunosuppressed patients are more likely to 
suffer herpes recrudescence with severe lesions occurring in those with AIDS
32
. As 
discussed subsequently, miRNA are known to influence the functional capacity of both 
innate and adaptive immune components. The role of innate immune events in the control 
of latency has received minimal attention, but there is strong evidence that the functional 
competence of viral specific CD8 T cell responses in the trigeminal ganglion influences 
 ="
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the stability of latency
30, 31
. Currently, we do not know if miRNA dysregulation impacts 
on the immune control of latency, but this topic is under active investigation by many 
groups that include our own. 
 
miRNAs, Robo4 signaling and angiogenesis 
The cornea’s function depends on its transparency since it must minimally 
interfere with the passage of light to the retina. This may be one reason the normal cornea 
lacks a blood vasculature since vessels diffract light. However, a significant consequence 
of HSV ocular infection is that pathological angiogenesis occurs, a process driven and 
facilitated by many factors
6
. A major angiogenic factor involved in corneal 
neovascularization (CV) is VEGF and counteracting VEGF and events set off when it 
binds to its specific receptors represents a valuable means of therapy
33
. We evaluated the 
role of anti-angiogenic roundabout 4 (Robo4) signaling in HSK. Robo4 is a guidance 
molecule expressed in brain that helps migration of neurons. But when expressed in 
blood vessels, it regulates angiogenesis
34, 35
. Slit2, a ligand for Robo4, when binds to 
trans membrane Robo4 receptor on blood vessel endothelial cells halts VEGF signaling 
in cancer systems and retinal models
36, 37
. We also observed Robo4+ blood vessel 
endothelial cells during HSK but the expression levels of Slit2 were found to be minimal 
in infected corneas. The provision of additional Slit2 protein resulted in significantly 
reduced CV after ocular HSV infection
38
. It remains to be seen whether additional 
angiogenesis regulatory mechanisms help to fine tune HSK pathological process. 
Pathological angiogenesis is also a major problem in neoplastic diseases and 
several species of miRNAs show changes that may account for the neovascularization. 
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The miRNA that showed the largest change of expression during angiogenesis was miR-
132
39
. We have also shown that miR-132 is also upregulated in animals with CV 
following HSV infection
12
. In the HSV system, the upregulation of miR-132 may be in 
part the consequence of stimulation, by an as yet unidentified mechanism by IL-17, a 
cytokine produced early in HSK pathogenesis by gamma delta cells of the innate immune 
system
40
. The upregulated miR-132 appears to act to augment VEGF signaling via an 
inhibitory effect on a negative regulator of VEGF function, Ras-GAP
39
. Of interest, 
inhibiting the expression of miR-132 using antagomirs in the form of nanoparticles was 
an effective means of diminishing CV as well as reducing the severity of HSK (figure 
1.3) (Table 1.1). Additionally, miR-132 blockade results in potent reduction in 
pathological angiogenesis in retinal models (Westenskow PD, et al. IOVS 2012; 53: 
ARVO E-Abstract 4120). Of note, this modality seems to work better than VEGF trap 
approaches and resulted in fewer off target effects and lower compensatory increases in 
angiogenic molecules, which is often the case with VEGF inhibition approaches
41
. It is 
also to be noted that miR-132 function depends on context. Thus, miR-132 promotes IFN 
production in Kaposi sarcoma herpes virus infected lymphatic endothelial cells
42
, 
regulates dendritic maturation in newborn neurons
43
. However, while it exerts anti-
inflammatory effect at neural immune interface
44
. Although we realize that miR-132 has 
an antiangiogenic function during HSK it is also possible that it interacts with other 
miRNAs in its modulation of tissue damage. 
In addition to VEGF, matrix metalloproteinase-9 (MMP-9) and other 
metalloproteinases play pivotal roles in promoting pathological blood vessel development 
during HSK
45
. Recent reports indicate that the regulation of MMP-9 expression involves 
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modulating effect by miRNAs. Accordingly, miR-885-5p, miR-491-5p, miR-212 and 
miR-132 negatively regulate the levels of MMP-9 expression in mammary glands and in 
cancer models
46, 47
. Our recent reports suggest upregulation of miR-132 and MMP-9 in 
corneas during HSK
12, 48
. miR-132 blockade induced reduction in CV and expression of 
miR-132 in blood vessel endothelial cells while MMP-9 in neutrophils make MMP-9 an 
unlikely target of miR-132 during HSK. While simultaneous expression of Ras-GAP and 
miR-132 in blood vessel endothelial cells from HSK or retinal models sets the angiogenic 
wheels in motion. However, targeting of MMP-9 with one or more species of inhibitory 
miRNAs with antagomir nanoparticles might represent a useful approach to therapy 
(Table 1.1). 
Almost certainly there are additional miRNAs that influence the many stages of 
CV. For example it is known that the activity of VEGF in the cornea is limited by being 
bound to a soluble form of one of its receptors
49
. HSV infection disrupts the balance 
between VEGF and its soluble receptor
48
, a process that likely involves expression 
changes in miRNAs. Additional events that could be regulated by miRNAs include 
disruption of blood vessel endothelial junctions, pericyte detachment, invasion of 
endothelial cells towards the center of the cornea as well as their proliferative effects. It is 
also likely that miRNAs fine tune the activity of apoptotic/anti apoptotic molecules in 
pathological blood vessel endothelial cells. Accordingly, the provision of appropriate 
miRNAs may induce apoptosis of endothelial cells and this may result in regression of 
established blood vasculature during HSK. Furthermore pathological blood vessels, 
which occur in corneas during HSK, are leaky and whether miRNAs influence leakiness 
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of such vessels by modulating the activity of src kinases or by regulating the functionality 
of proteins involved in maintenance of endothelial junction integrity requires exploration. 
 
miRNAs and Inflammation 
Several types of innate immune sensors are triggered when HSV infects the 
cornea and many molecules with diverse function are rapidly produced. These include 
pro-inflammatory cytokines, chemokines, interferons and angiogenic factors such as 
VEGF. Among the best studied innate sensors are the toll like receptors with TLR2, 
TLR3 and TLR9 all involved as HSV sensors
50, 51
. Additional intracellular sensors may 
also recognize HSV and these include the recently described sensor STING that 
recognizes HSV induced membrane fusion and inflammasomes which lead to production 
of the pro-inflammatory cytokine IL-1b
52-54
. The innate recognition phase sets the scene 
for both   infection control, mediated by interferons and innate effectors such as 
granulocytes, macrophages and NK cells, as well as establishing conditions that result in 
tissue damage orchestrated by adaptive components of immunity. Most 
persons with HSV keratitis resolve infection with little or no stromal disease. Those less 
fortunate develop HSK with this outcome most likely to occur after one or more 
recurrences from latency. Why individuals differ in their response pattern to HSV 
infection remains poorly understood but differential regulation of innate and adaptive 
immunity by one or more species of miRNA is a likely possibility that merits 
investigation.  
With regard to the extent of innate immune sensing, evidence accumulates 
showing that TLR function is subject to control by numerous miRNA species. As lucidly 
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reviewed by O'Neil and colleagues
55
, miRNAs may regulate the strength, location and 
timing of TLR responses and also appear to control the switch from an early innate 
immune induced pro-inflammatory response to conditions that represent the resolution 
phase of the inflammatory process. In fact, at least 10 miRNAs are upregulated when one 
or more TLRs engage their ligands and others are down regulated. Apparently the TLRs 
themselves are not targeted by miRNAs and regulation mainly affects the activity of 
signaling molecules
55
. In this context, TLR signal transducers such as MyD88, IRAK, 
TAB, TRAF6, IKK are all targets of one or more species of miRNAs. In addition, 
transcriptional factors induced by TLR ligation are subject to miRNA regulation and 
some miRNAs also degrade the products of TLR signaling
55
. One such miRNAs is let-7 
that binds to the mRNA of IL-6 and decreases expression of this cytokine which is a 
major participant in HSK pathogenesis and also a stimulant of the angiogenic factor 
VEGF
56
. Additionally, other cytokines such as TNF-!, IL-10, IL-12 and IFN-" are 
directly repressed by miRNA action
55
. However, what role if any these aforementioned 
miRNAs play during the innate phase of HSK pathogenesis remains to be seen. 
Additional components of innate responses to HSV include granulocytes, 
macrophages and NK cells. The function of all of these cell types is influenced by 
miRNA expression
57-59
. For example, miR-223 regulates the proliferation and activation 
status of neutrophils
60
. Furthermore, its also conceivable that miRNAs are involved in 
regulating tissue damaging molecules such as the production of reactive oxygen and 
nitrogen radicals by neutrophils and the generation of neutrophil extracellular traps. 
Macrophage function during infection is influenced my several miRNAs that include 
miR-155, miR-146, miR-132, miR-147, miR-9, let-7e, miR-27b and miR-125b
61, 
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62
. Similarly NK cell killer function, such as granzyme activity, is influenced by miR-155 
and miR-27a*
63, 64
. 
Although it is still early days, it has become evident that miRNAs derived from 
innate immune cells, and perhaps exported from such cells in the form of exosomes
65
, are 
important regulators of inflammation and the miRNAs also influence the balance of 
adaptive immune responses that determine whether immunity or tissue damage ensues. 
Indeed, the enforced expression of TLR induced miRNAs might well turn out to be 
useful negative regulators of the inflammatory process, as well as tools to shape the 
desired pattern of adaptive immunity to one that has minimal tissue damage.  
As mentioned in a previous section, the tissue damaging events in HSK are 
orchestrated predominantly by effector CD4 T cells with the actual damage mainly 
mediated by neutrophils and macrophages
9, 66, 67
. Multiple miRNAs are known to 
influence the induction and effector function of T cells, the recruitment and activation of 
inflammatory cells as well as the participation of additional cell types such as regulatory 
T cells involved in lesion resolution. The topic is complex and fast moving. In 
consequence, we mention only what may be the most pertinent miRNA expression 
events that impact on the pathogenesis of HSK and which represent promising candidates 
for therapeutic manipulation to change the outcome of disease. 
The miRNA miR-23b, generally implicated in liver regeneration
68, 69
, is a likely 
candidate since it also acts as a critical regulator in several autoimmune syndromes in 
humans and mice whose pathogenesis has similarity to HSK
70
. Accordingly, miR-23b 
normally plays an anti-inflammatory role by inhibiting the transcription factor NFkB that 
in turn regulates the production of numerous proteins involved in tissue damage, as well 
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as the recruitment of pro-inflammatory cells. The expression of miR-23b is down 
regulated by a still poorly understood mechanism when the pro-inflammatory cytokine 
IL-17 binds to its receptor. As a consequence, NFkB becomes hyperactivated and 
inflammation progresses. Although HSK is mainly orchestrated by inflammatory Th1 
cells, the cytokine IL-17A produced by innate cells does play a prominent role during the 
onset of HSK and may also participate in neovascularization
40, 71
. Thus, it is conceivable 
that miR-23b dysregulation occurs during HSK and this may influence the severity of 
lesions that ensue. This aspect merits investigation, as does the prospect that 
administration of additional miR-23b may represent a useful adjunct to therapy (Table 
1.1). 
miR-155 is another miRNA frequently implicated in inflammatory lesions and 
serves to positively regulate inflammation
72-74
. It is also required for normal immune 
function
75, 76
 as well as for generation of pathogenic T cells 
77
 and act as an oncomir in 
various cancers
78, 79
. Animals deficient in miR-155 because of gene knockout (KO) are 
resistant to the induction of some autoimmune diseases
72, 77
. We have also observed that 
miR-155 KO animals develop significantly reduced HSK lesions, although they become 
highly susceptible to virus induced encephalitis (S. Mulik, S. Bhela and B.T. Rouse, 
unpublished observations). The miR-155 may influence tissue damage in several ways 
that include regulating the production of critical chemokines such as those for neutrophils 
which play a prominent role in HSK pathogenesis
73
. Our preliminary results in the HSK 
system indicate that chemokines such as the neutrophil attracting CXCL1, are reduced in 
miR-155 deficient animals. In addition, as is shown in some autoimmune models, miR-
155 deficiency may also result in the increased production of the critical anti-
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inflammatory mediator IL-10, as well as reduced generation of Th1 and Th17 effectors 
that orchestrate HSK lesions
77
. In some inflammatory and autoimmune settings, loss of 
miR-155 also results in profound reduction in the inflammatory milieu as well as tissue 
damage
74
. Since counteracting T cell function and inflammation would be useful to limit 
tissue damage, administering antagomirs to diminish miR-155 expression may be a 
valuable approach to achieve this objective during HSK, as we are currently evaluating 
(Table 1.1). 
There are other miRNAs that we speculate may significantly influence the 
pathogenesis of HSK. In this regard, miR-29 was recently shown to target Tbet and 
Eomes transcription factors, both of which promote IFN-" production by Th1 cells
80
, 
central orchestrators of HSK pathogenesis. Similarly, miR-326 and miR-301a are 
involved in the generation of Th-17 cells, a subset recently shown to influence the later 
stages of HSK
40
. Inhibition of miR-326/301a resulted in attenuated EAE lesions in mice 
via effects on Th-17 cells
81, 82
. miRNAs are also known to be involved in sequential steps 
of T cell proliferation. For example, miR-142-3p/5p, miR-17 and miR-20a inhibit T cell 
activation
83, 84
. On the other hand, IL-2 induced miR-182 degrades Foxo 1 and promotes 
clonal expansion of activated helper T lymphocytes
85
.  
It is now realized that fully differentiated T cells, once considered a stable 
population, may take on other activities depending on environmental cues. For example, 
Tregs can lose their regulatory function and adopt effector phenotypes
86
. It appears that 
changes in miRNA expression may be involved in this cellular functional plasticity
87
. For 
example, in response to retinoic acid and TGFb, Tregs increase miR-10a expression that 
limits their conversion into follicular helper T cells and Th-17 cell subsets. Whether and 
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how miRNAs influence various stages of T cell activation or T cell flexibility during 
HSK is largely unknown (Table 1.1).  
 
miRNAs in anti-inflammation and resolution 
The aim of all research on inflammatory diseases is to discover optimal ways to 
resolve lesions and understand how they function at a mechanistic level. Under natural 
circumstances, inflammatory responses are usually resolved either because the inciting 
stimuli are removed and/or because the balance of host events changes. Such changes 
could be influenced, at least in part, by dysregulation of one or more species of miRNAs. 
Several host events can push inflammation towards resolution. These include the 
expansion of regulatory T cells, the increased activity of several cytokines particularly 
IL-10 and TGFb, the production of one or more species of host galectins as well as 
multiple specialized proresolving mediators derived from polyunsaturated fatty acids. 
How miRNA changes relate to the increased activity of these anti-inflammatory and 
inflammation resolving events is beginning to be unraveled, at least for some of them. 
Two such candidates are miR-146a and miR-21 that play prominent roles in protecting 
tissues from inflammatory damage
62
. 
miR-146a exerts this regulatory effect by policing NF-#B dysregulation. In the 
context of innate immunity, miR-146a inhibits TLR signaling and NF-#B activation and 
dampens the production of pro-in$ammatory mediators such as IL-6 and TNF-!
88
. A 
diminished miR-146a response also results in malfunction of the adaptive immune 
responses. Of note, regulatory T cells express high levels of miR-146a and Treg specific 
deletion of miR-146a expression leads to severe autoimmune disease due to uncontrolled 
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Th-1 responses
89
. This further corroborates a regulatory role of miR-146a in restraining 
inflammation and maintaining peripheral tolerance. In addition miR-146a was implicated 
in resolving both CD4 and CD8 T cell mediated immunopathological responses
90
. In 
mice, TCR stimulation induced expression of miR-146a and T cell specific miR-146a 
deficiency resulted in hyperactive acute antigenic responses, chronic inflammatory 
autoimmune responses as well as T cell mediated autoimmune disease
90
. It will be of 
interest to see what effects miR-146a overexpression will have on the balance between 
protective Tregs and eye damaging Th-1 cells during HSK. We speculate that the potent 
regulatory environment induced by miR-146a may hamper lesion development (Table 
1.1). Moreover, dampening of pro-inflammatory milieu by administering additional miR-
146a could represent a useful form of therapy. 
Another miRNA likely involved in resolution is miR-21. This miRNA halts 
inflammation in various models partly via its ability to induce IL-10
91, 92
, a molecule 
previously shown to suppress HSK lesions
93
. However, miR-21 may enhance vascular 
inflammation in atherosclerosis
94
. miR-21 may also shift the Th1/Th2 balance towards 
the Th2 type
95
 with miR-21 deficient mice demonstrating enhanced Th1 associated 
responses
96
. Conceivably, overexpression of miR-21 could help to modulate Th1 
mediated tissue damage during HSK an issue that merits further investigation (Table 1.1).  
An additional approach to modulate the severity of inflammatory diseases is to 
expand or activate regulatory T cells whose activity is also influenced by expression 
levels of several miRNAs
97, 98
. These include miR-10a, miR-146a and miR-155
89, 99-101
, 
but their contribution in modulating ocular damage is yet to be analyzed. Conceivably, 
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the above mentioned miRNAs will help shift the balance towards resolution events in 
tissue damaging settings. 
In the resolving phase of inflammation, changes in expression of several 
mediators occur. One prominent change is in the lipid mediators derived from 
polyunsaturated fatty acids. Thus whereas during the pro-inflammatory phase 
leukotrienes and prostaglandins predominate, during resolution there is a switch to lipid 
mediators referred to as specialized prosesolving mediators (SPM)
102
. This switch may be 
regulated, at least in part, by changes in miRNA expression.  For example, miR-292-2 
levels increase for reasons that include neutrophil death with miR-292-2 targeting the 
mRNA of the lipoxygenase enzyme responsible for generating the pro-inflammatory 
leukotrienes
103
. Additionally miR-292-2 increases, by an unknown mechanism, the 
synthesis of SPM such as resolvins and protectins. In HSK, where in some 
instances resolution can be delayed, it is conceivable that miR-292-2 levels are 
suppressed perhaps in situations when viral replication levels are elevated.  
The observation that SPMs appear to account for resolution under natural 
circumstances has led to the development of synthetic formulations that are proving 
valuable to control inflammatory lesions that include HSK
104, 105
. It has also become 
evident in recent studies from the Serhan group that levels of multiple miRNAs change in 
response to synthetic SPM therapy
106
. For example, resolvin administration fine-tunes 
levels of miRNAs such as miR-21, miR-146b, miR-208a and miR-292-2 in various tissue 
damaging settings
106, 107
. These miRNAs act by changing the expression of several 
inflammatory mediators. For example, miR-21 and miR-208a induce IL-10 production 
during the resolution phase thus exerting strong anti-inflammatory effect. miR-146b also 
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regulates levels of IL-8 and RANTES, both powerful chemo attractants that recruit 
leukocytes into in$amed areas, while miR-292-2 induces the production of more SPM. 
We speculate that the provision of SPM during HSK may act by inducing the expression 
of pro resolution miRNAs that include miR-21, miR-146b, miR-292-2 while levels of 
inflammatory and angiogenic miRNAs (miR-155 and miR-132) might diminish (fig 1.4) 
(Table 1.1). Our unpublished observations support this claim. Whether any group of 
miRNAs are sufficient to activate a resolution program is currently not known. If it can 
be accomplished the inclusion of pro-resolution miRNAs would be valuable when 
designing therapeutics to counteract HSK lesions. 
 
Potential of miRNA targeting 
 Manipulation of disease associated microRNAs offers unique opportunities but 
poses challenges as regards of delivery, target site accessibility and off target effects. 
Progress on this topic has occurred with several reports showing amelioration of diseases 
via blockade of miRNAs using modified antagomirs as is the case with locked nucleic 
acid (LNA) or antagomirs given in nanoparticles
108, 109
. Our own study evaluated the 
potential of miR-132 inhibition using antagomir-132 histidine lysine nanoparticle 
approaches that led to potent reduction of CV. This was also recently confirmed in retinal 
models by Martin Friedlander and David Cheresh groups who showed that nanoparticle 
mediated miR-132 blockade is more efficacious (Westenskow PD, et al. IOVS 2012; 53: 
ARVO E-Abstract 4120) than conventional VEGF inhibition therapies and results in 
lower off target effects and fewer compensatory increases in angiogenic genes compared 
to VEGF targeting. Several other recent reports support miRNA inhibition approaches to 
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modulate disease pathologies. For example, miR-122 shows effects against Hepatitic C 
virus infection
110
; miR-155 is effective in the inflammatory disease models, EAE
111, 112
 as 
well as against B cell lymphoma
79, 113
. Additionally, miR-21 is effective to inhibit 
lupus
28
. We are investigating the potential of slow antagomir release eye drop formulated 
nanoparticles to intercept HSK pathogenesis and believe that the cocktail of miRNAs 
given in nanoparticles locally may confer therapeutic benefit against HSK. 
 
Concluding remarks 
 Although published information about the regulatory role of miRNAs during HSK 
is minimal we can surmise that multiple miRNAs are likely to influence all of the many 
events that occur during HSK pathogenesis. We can also surmise that changing miRNA 
responses could represent a useful approach to therapy especially because several phases 
of HSK could be targeted simultaneously using cocktails of multiple miRNAs mimics 
and antagomirs. The major practical problem would be how to administer the cocktail 
and how frequently this must be done to achieve therapeutic efficacy. There have been 
some reports that show the ease of delivery of siRNA to localized areas such as the eye, 
lung and skin and these siRNAs were shown to be effective in in vivo silencing
114,115
. In 
fact most of these siRNAs are under clinical trials. Although only one such miRNA 
targeting drug is in clinical trial (miravirsen). It is conceivable many more miRNA 
intervention therapies could enter clinic in the near future. 
It is also likely that the composition of the therapeutic cocktail would need to differ at 
different phases of HSK lesions. Most likely treatment close to the onset of lesions would 
stand the best chance of success. We would speculate that using miRNAs or antagomirs 
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to increase IL-10 expression, to block the recruitment of inflammatory cells to the 
corneas and to limit the extent of CV would be successful strategies. At later stages 
switching the inflammation to the resolution phase would be desirable as might be 
achieved by changing the expression of miRNAs involved in SPM production. Although 
therapy with miRNA has therapeutical advantages, it remains to be seen if the approach 
would be practical or economical compared to traditional therapies in current use. 
Answering these questions will require further research. Optimistically nanoparticles 
containing multiple miRNAs and antagomirs would be administered once or twice daily 
and be therapeutically effective. 
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Appendix 
Table 1.1: Speculative role of miRNAs, their blockade/overexpression and reduction 
in HSK lesion severity (Mild +, Moderate ++, Severe +++). 
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Figure 1.1. miRNA biogenesis: The generation of miRNAs involves nuclear and 
cytoplasmic processing steps. In the nucleus, pri-miRNAs, transcribed by RNA 
polymerase from DNA, are processed by Drosha into pre-miRNAs which are then 
transported to cytoplasm via exportin 5. Once in cytoplasm, these pre-miRNAs are 
recognized and cleaved by Dicer into 20-22 bp duplexes that enter RISC. In RISC, 
passenger strand is cleaved while guide strand directs RISC machinery to target mRNAs 
resulting in mRNA degradation or inhibition of protein translation. 
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Figure 1.2. Speculative role of miRNAs in HSV-1 reactivation from latency. After 
primary infection, HSV-1 becomes latent in trigeminal ganglia. Certain conditions such 
as sunburn, stress, impaired T cell responses, immunosuppression can reactivate virus to 
come to the peripheral sites (eyes, oral mucosa) to induce lesions. miRNAs may regulate 
all of these above mentioned stimuli. Sunburn can trigger HSV reactivation and it 
involves changes in expression levels of miRNAs (miR-21, miR-203). Likewise, stress 
induced glucocorticoids induce changes in miRNAs (miR-15/16 and miR-223) and also 
lead to epigenetic modifications, a process which involves miRNA change (miR-44 and 
miR-1) and is implicated in maintenance of latency. CD8 T cells patrol trigeminal ganglia 
and inhibit HSV reactivation but functionality of CD8 T cells can also be modulated by 
Stress and 
Glucocorticoids 
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CD8 T cells 
? HSV encoded 
miRNAs 
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oral mucosa) 
? (miR-21 and miR-24)  
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miRNA activity (miR-21 and miR-24). The role of HSV encoded miRNAs in HSV 
reactivation remains unknown so far. 
 
Figure 1.3 Illustration of antagomir-132 mediated inhibition of corneal 
neovascularization (CV). Left panel describes outcome (CV) in HSV infected untreated 
mice: HSV infection leads to upregulation of IL-17 in corneas. IL-17 (along with IL-6 
and virus infected epithelial cells) increases VEGF (probably via increasing IL-1b, IL-6 
and Cxcl1) levels in the eyes. VEGF thus acting through VEGFR2 receptors on the blood 
vessel endothelial cells upregulates miR-132 expression via CREB transcription factor. 
MiR-132 removes RasGAP (intrinsic inhibitor of Ras) leading to activation of Ras and 
CV. Right panel describes modulation of CV by miR-132 silencing: Administration of 
antagomir-132 nanoparticles leads to deposition of antagomir-132 cargo in blood vessel 
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endothelial cells resulting in silencing of miR-132. This leads to higher levels of 
RasGAP, which thereby inhibits angiogenic Ras activity resulting in inhibition of CV 
(Reprinted from Am J Pathol 2012, 181:525-534 with permission from the American 
Society for Investigative Pathology). 
 
Figure 1.4. Specialized pro-resolution mediators (SPM) and miRNA mediated 
resolution of HSV induced ocular inflammation: Speculations. The provision of SPM 
during HSK may result in changes in levels of various miRNAs associated with 
resolution. SPM could increase expression of miR-21 and miR-208a both of which 
induce anti-inflammatory cytokine, IL-10. SPM can also increase miR-146b expression 
and miR-146 lowers levels of IL-8, a chemokine crucial for neutrophil recruitment to 
eyes. miR-292-2 induced by SPM gives positive feedback for more SPM production. The 
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administration of SPM may also lower levels of miR-132 and miR-155 involved in CV 
and inflammation respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 87"
"
Part II 
 
Activation of endothelial roundabout receptor 4 
(Robo4) reduces the severity of virus induced keratitis 
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Research described in this chapter is reproduced from a publication accepted in Journal 
of Immunology by Mulik S, Sharma S, Suryawanshi A, Veiga-Parga T, Reddy PB, 
Rajasagi
 
NK and Rouse
 
BT. 
Mulik S, Sharma S, Suryawanshi A, Veiga-Parga T, Reddy PB, Rajasagi NK, Rouse BT. 
Activation of endothelial roundabout receptor 4 reduces the severity of virus-induced 
keratitis. J Immunol. 2011 Jun 15; 186(12): 7195-204. Copyright 2011.  The American 
Association of Immunologists, Inc. 
Abstract 
Anti angiogenic molecules exert a feedback control to restrain pathological angiogenesis, 
which include physical binding or inhibition of angiogenic signaling in blood vessel 
endothelial cells. The latter is the case when Slit2 ligand dependent activation of the 
blood vessel endothelial cell receptor roundabout 4 (Robo4) occurs. In this study, we 
demonstrate that Robo4 receptors are up regulated following herpes simplex virus (HSV) 
infection of the eye on the majority of the new blood vessel endothelial cells that occur in 
the corneal stroma. However, expression levels of the ligand for Robo4 receptors, Slit2, 
was not significantly increased during the disease process and the knockdown of Slit2 
gene expression using lentiviral shRNAs had no effect on the extent of pathological 
angiogenesis. In contrast, providing additional Slit2 protein by subconjunctival 
administration resulted in significantly reduced angiogenesis. The Slit2 binding to Robo4 
was shown to block the downstream VEGF signaling molecules Arf 6 and Rac 1 and 
reduced the anti-apoptotic molecule Bcl-xL in blood vessel endothelial cells. Our results 
indicate that augmenting the host Robo4/Slit2 system could provide a useful therapeutic 
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approach to control pathological angiogenesis associated with HSV induced stromal 
keratitis (SK). 
 
Introduction 
Ocular Herpes simplex virus (HSV) infection may result in a chronic immuno-
inflammatory lesion in the corneal stroma that often results in blindness (1-4). 
Understanding the pathogenesis of stromal keratitis (SK) lesions has mainly come from 
animal model studies, particularly using the mouse (5). Such studies have revealed that 
neovascularization of the normally avascular cornea is a key event in SK pathogenesis (6-
8). In consequence, understanding how to control pathological angiogenesis, which is 
also a critical event in human SK, is relevant since it could result in improved therapy. 
Many molecules induced in the eye in response to infection can contribute to 
neovascularization with the VEGF family molecules, particularly VEGF-A signaling via 
VEGFR-2 receptors, being the major stimulus for angiogenesis (9-11). Curiously, VEGF-
A is produced within the normal cornea, but it fails to drive blood vessel development 
since it is bound to an excess of the soluble form of one of its receptors (12-14). Virus 
infection results in the increased synthesis of VEGF-A as well as some other angiogenic 
molecules (15, 16) and, in addition, causes the breakdown of the VEGF-A/soluble 
receptor bond (Manuscript accetped for publication). Interference with VEGF levels, or 
blocking the binding or signaling of receptors are the major approaches so far evaluated 
to control pathological neovascularization (6, 7, 9, 17). However, the host itself also has 
one or more means of shutting down VEGF induced angiogenesis (13). For example, the 
Robo4 receptor that is expressed by endothelial cells in newly formed blood vessels can 
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transduce signals to the cell that will negate or counteract the positive stimulus caused by 
VEGF binding to its receptors (18, 19). Robo4 receptors can be activated by the host 
ligand, Slit2, that is produced in some pathological lesions by vascular endothelial cells 
(18, 20). Accordingly, the balance between the positive signals produced by VEGF may 
become modulated and perhaps terminated by Slit2 induced Robo4 receptor activation. In 
some circumstances, such as in laser induced retinopathy, Robo4 knockout mice revealed 
an accelerated pathological angiogenesis process (18). Additionally, Slit2/Robo4 
signaling reduced vessel permeability in the lung and other organs and protected mice 
from a pathogen induced cytokine storm (21).  
Currently, no reports have evaluated the relevance of the Slit2/Robo4 regulatory system 
in an infectious disease that involves pathological angiogenesis. This issue is addressed 
herein using ocular infection with HSV that causes neovascularization of the cornea and 
the blinding lesion stromal keratitis. Our results show that following HSV infection, 
Robo4 transcripts were significantly up regulated in corneal tissues with the majority of 
endothelial cells of the newly developed blood vessels expressing Robo4 receptors. 
However, the Robo4 ligand, Slit2 transcripts and protein were not significantly increased 
after HSV ocular infection. This could mean that the amount of Slit2 available for 
binding to Robo4 receptors was limited and that the Slit2/Robo4 host regulatory system 
was not contributing to effectively control angiogenesis during SK. In support of this 
notion, blocking Slit2 gene expression using lentiviral shRNA vectors had no effect on 
the extent of angiogenesis, but in contrast, the provision of additional Slit2 protein by 
sub-conjunctival injection significantly reduced neovascularization. The results of these
 
studies have therapeutic implications for the control of HSV-induced vision
 
loss. 
 8;"
"
Materials and Methods 
Mice: Female 6-8 wks old C57 BL/6 mice were purchased from Harlan Sprague Dawley 
Inc. (Indianapolis, Indiana, USA). All mice were housed conventionally in animal facility 
at the University of Tennessee. All investigations followed guidelines of the Association 
for Research in Vision and Ophthalmology resolution on the use of animals in research. 
Virus: HSV-1 strain RE Tumpey was propagated in Vero cell monolayers (ATCC nol 
CCL81). Infected Vero cells were harvested, titrated and stored in aliquots at -80
0
C until 
used. 
Corneal HSV-1 infection and scoring: Corneal infections of mice were performed 
under deep anesthesia. The mice were lightly scarified on their corneas with a 27-gauge 
needle, and a 3 &l drop containing 10
4
 PFU of HSV-1 RE Tumpey was gently applied to 
one eye. The development of SK lesion severity and angiogenesis in the eyes of mice was 
examined by slit-lamp biomicroscopy (Kowa Company, Nagoya, Japan). The scoring 
system used was as follows: 0, normal cornea; 1, mild corneal haze; 2, moderate corneal 
opacity; 3, severe corneal opacity; 4, opaque cornea and ulcer; 5, corneal rupture. The 
severity of angiogenesis was recorded as described previously (22). According to this 
system, a grade of 4 for a given quadrant of the circle represents a centripetal growth of 
1.5 cm towards the corneal center. The score of the four quadrants of the eye were then 
summed to derive the neo vessel index (range 0 16) for each eye at a given time point. 
Sub-conjunctival injections: Sub-conjunctival injections were performed as reported 
previously (22). Briefly, these injections were carried out using a 2-cm, 32-gauge needle 
and syringe (Hamilton, Reno, NV) to penetrate the perivascular region of conjunctiva and 
appropriate amount of Slit2 protein (R & D systems, Minneapolis, MN) was administered 
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into sub-conjunctival space. Slit2 protein used in this study is a Gln26-Gln900 amino 
terminal fragment, which is expressed in CHO cells. Mock treatment was given in control 
mice. 
Mice treatment with recombinant Slit2 protein: The mice ocularly infected with HSV-
1 RE Tumpey were separated into two groups. The Slit2 protein (1 &g) was given to one 
group in 10 &l PBS sub-conjunctivally at 2 days p.i. with additional doses on alternate 
days until day 12 post infection. The Slit2 treatment was begun at day 7 in another 
experiment with additional doses on alternate days until day 13 post infection. Control 
group received mock drug sub-conjunctivally with the same regimen for respective 
experiment. These animals were carefully followed for the progression of angiogenesis 
and SK development. All experiments were repeated at least two times. 
Purification of endothelial cells: The excised corneas were pooled and digested with 60 
U/ml Liberase for 35 minutes at 37
0
C in a humidified atmosphere of 5% CO2. The single 
cell suspension was prepared and stained with anti CD 31-FITC for 30 minutes on ice. 
The FITC+ endothelial cells (CD 31+) were sorted using a FACS sorter. The purity at the 
extent of 80-90% was achieved. These sorted endothelial cells were used for pull down 
assays, for detection of Bcl-xL, cyclin D1 and caspase 3 proteins and for confocal 
microscopy. 
Confocal microscopy. For confocal staining, the purified endothelial cells were taken on 
a slide using cytospin and fixed in 4% para!formaldehyde at room temperature for 10 
min. The cells were blocked with 10% goat serum containing 0.05% Tween20 and 1:200 
dilution of Fc block (Clone 2.42G2; BD Biosciences Pharmingen, San Diego, CA). Rat 
anti!Robo4-PE (R & D systems, Minneapolis, MN) and Rat anti!CD31-FITC (Clone: 
 8="
"
390, BD Pharmingen) were diluted in 1% BSA containing 0.1% Triton!X and incubated 
at room temp for 1 hr. After incubations, slides were washed several times with PBST 
and mounted with Prolong gold antifade mounting media (Invitrogen) and visualized 
under a confocal microscope. 
Flow Cytometry: The corneal single cell suspensions were prepared following Liberase 
digestion of corneas. These corneal cell suspensions were stained for different cell 
surface molecules for FACS. Shortly, cell suspensions were incubated with CD45-
allophycocyanin (30-F11), CD11b-PerCP (M1/79), Gr1-PE (1A8), CD 4-
allophycocyanin (RM4.5), CD31-FITC (All from BD Biosciences Pharmingen) and 
Robo4-PE (R & D systems, Minneapolis, MN) for 30 minutes on ice. Thereafter, cells 
were washed thrice and resuspended in 1% para-formaldehyde. The stained samples were 
acquired with a FACS Calibur (BD Biosciences) and the data were analyzed using the 
FlowJo software. 
Quantitative PCR (QPCR): Total mRNA was isolated from corneal cells using TRIzol 
LS reagent (Invitrogen). The cDNA prepared using 1 µg of RNA was used for subsequent 
analysis. QPCR was done using SYBR Green PCR Master Mix (Applied Biosystem, 
Foster City, CA) with iQ5 real-time PCR detection system (Bio Rad, Hercules, CA). The 
expression levels of Slit2 and Robo4 were normalized to %-actin with 'Ct method and 
relative quantification between control and infected mice was performed using the 2!
''Ct
 
formula. The primers used were as follows. %-actin forward 
CTACCTCATGAAGATCCTGACC, %-actin reverse 
GTCTAGAGCAACATAGCACAGC; Slit2 forward 
CCTTCTGAATGTACCTGCTTGG, Slit2 reverse GTAGTTAGAGAGTTCCTTCGGG; 
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Robo4 forward GACCTATATGTGTATGGCCACC, Robo4 reverse 
CTCTAGATGTTCCTTGTGGTCC, Cxcl2 forward CCAACCACCAGGCTACAG, 
Cxcl2 reverse CTTCAGGGTCAAGGCAAAC, Nos2 forward 
TGGATTGTCCTACACCACA and Nos2 reverse CTCCAATCTCTGCCTATCC. The 
primers for Il1b, IFNg, Il6 and Cxcl1 were already available in the lab (Manuscript 
accepted for publication in Journal of Virology). 
Reverse Transcription Polymerase chain reaction (RT-PCR): RT-PCR for the 
presence of Slit2 and Robo4 transcripts was done according to the manufacturers protocol 
(Promega, Madison, WI). The amplified products were resolved on 1% agarose gel. 
Primers for RT-PCR were as follows. %-actin forward 
CTACCTCATGAAGATCCTGACC, %-actin reverse 
GGCATAGAGGTCTTTACGGATG; Slit2 forward 
GGGAACGACAGTTTCATAGGACTC, Slit2 reverse 
GTAGTTAGAGAGTTCCTTCGGG; Robo4 forward 
GGAGTGACCTTAAGATCTGGCAAC and Robo4 reverse 
CTAGTAGCAGCAACCAGAGTAG. 
Western blot analysis: The corneal cells were lysed and total protein in the supernatants 
was quantified using BCA protein assay kit (Thermo scientific, Waltman, MA). Samples 
were denatured in Laemmli buffer and resolved by SDS-PAGE and proteins were 
transfered onto a PVDF membrane. The membrane was blocked with 5% BSA in Tris-
buffered saline with Tween 20 at 4
0
C overnight and subjected to incubation with specific 
primary and secondary antibodies. Proteins bands were visualized using 
chemiluminiscent HRP substrate (Millipore, Billerica, MA). After keeping in stripping 
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buffer for 10 minutes, the membrane was re-probed using anti %-actin antibody. The 
antibodies used were as follows: goat anti mouse Robo4 (C-20), goat anti mouse Slit2 
(D-16), anti %-actin (C 4), mouse Bcl-xL (4), mouse cyclin D 1(72-13G), goat caspase 3 
(T-20), goat anti mouse IgG-HRP and donkey anti goat IgG-HRP (All these antibodies 
were procured from Santa Cruz biotechnology), mouse Arf 6 (26186D) (Thermo 
scientific, USA) and mouse Rac 1(89856D)(Thermo scientific). 
Arf 6
 
activation assay: Arf 6 activation assays were performed as reported previously 
(19). These experiments were carried out using Active Arf 6 pull down and detection kit 
(Thermo scientific) according to manufacturer’s protocol. Briefly, resin slurry was added 
to the spin cup in a collection tube and 100 µg GST GGA3-PBD fusion protein with 800 
µg total protein (corneal cell lysate) was added to this slurry. This was incubated at 4
o
C 
for 1 hour and finally 50 µl reducing sample buffer was added and GTP-Arf 6 was pulled 
down and subsequently analyzed by WB. These experiments were repeated two times. 
Rac 1 activation assay: The Rac 1 activation assays were carried out as described 
previously (19). The EZ-Detect™ Rac 1 activation kit (Thermo scientific) was used to 
isolate active Rac 1 from corneal cell lysates. The immobilized glutathione disc was place 
into a spin column and 20 µg of GST-human Pak1-PBD was added to it. Immediately, 
700 µg total protein (corneal cell lysate) was added to the spin column and it was 
incubated for 1 hour at 4
o
C with gentle rocking. Finally, 50 µl of 2X SDS sample buffer 
containing %-mercaptoethanol was added to the resin and mixture was heated at 100
o
C for 
5 min. Samples were analyzed by WB. These experiments were repeated two times. 
Retrovirus based RNAi: Slit2 shRNA lentiviral particles and control lentiviral particles 
were procured from Santa Cruz biotechnology. These lentiviral particles contain 3-5 
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expression constructs each encoding Slit2 specific shRNA while control lentiviral 
particles encode scrambled sequences. The knockdown of Slit2 in MKT cells was 
performed using the manufacturer’s protocol. Briefly, cells were transfected when they 
were 50% confluent. Polybrene was added at a final concentration 5 µg/ml and Slit2 
shRNA/ control lentiviral particles (ranging from 1 x 10
5
- 5 x 10
5
) were added to cells. 
Medium was changed after 12 hrs and cells were analyzed by QPCR for Slit2 knockdown 
over 2-4 days after transduction. For in vivo experiments in HSV infected mice, 1 x 10
5
 
Slit2 shRNA/control lentiviral particles were inoculated sub-conjunctivally starting at day 
1 with additional doses on alternate days until day 11 and mice were monitored for the 
progression of angiogenesis and SK. 
Statistics: The statistical significance for SK lesion severity and angiogenesis between 
two groups was determined using unpaired two-tailed student's t test. One way ANOVA 
with Bonferroni’s post hoc test was used to calculate the level of significance for some 
experiments. P ( 0.001 (***), P ( 0.01 (**), P ( 0.05 (*) were considered as significant. 
All experiments were repeated at least two times and results are expressed as means 
±SEM. For all statistical analysis, GraphPad Prism software was used. 
 
Results 
Expression of Robo4 and Slit2 after HSV infection 
The pattern of expression of Robo4 and Slit2 gene and protein expression was measured 
at various time points after HSV infection focusing on time points when 
neovascularization was prominent and SK lesions clinically apparent. Thus, our aim was 
to find evidence for a possible role of the Robo4/Slit2 interaction in constraining VEGF 
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driven angiogenesis and vascular permeability. Corneas were collected at different times 
post HSV infection, dissected free of normal limbal blood vessels and samples processed 
either to collect vascular endothelial cells for phenotyping, or to prepare corneal RNA 
samples to quantify Robo4 and Slit2 mRNA levels by quantitative PCR (QPCR). As 
shown in fig 2.1A, naïve avascular corneal samples do express Robo4 mRNA (likely 
produced by corneal epithelial cells) but Slit2 mRNA was barely detectable. The fact that 
naïve corneas express Robo4 and Slit2, was also demonstrable by western blotting (fig 
2.1B&C) and the positive controls for Robo4 and Slit2 were kept kidney and brain due to 
the expression pattern of these molecules reported previously (23, 24). Changes in the 
levels of Robo4 mRNAs (probably from blood vessel endothelial cells) occurred as early 
as day 2 after HSV infection, and levels peaked during the clinical phase (day 7-day 14) 
reflecting the appearance of neovascularization in the infected eye (fig 2.1D). However 
Slit2 expression levels did not change significantly over the course of events (fig 2.1E). 
By day 2, mRNA levels for Robo4 were increased by 28 fold but Slit2 only by 2.9 fold. 
At the time of overt neovascularization, on day 9 post infection, Robo4 mRNA was 
elevated by 51 fold, but Slit2 mRNA only 3.6 fold (fig 2.1D&E). Corneal extracts were 
also analyzed for Robo4 and Slit2 proteins by western blotting on day 9. Compared to 
controls, the elevated expression of Robo4 was evident with little change in Slit2 levels 
(fig 2.1F). 
  Cells isolated from infected corneas at different times post infection were sorted 
for CD31+ cells (a marker for vascular endothelial cells) and the expression of Robo4 
was measured on such cells (fig 2.2A). Firstly, we could show that the percentage of 
CD31+ cells that expressed Robo4 protein changed with time. Thus, at the earliest time 
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point (day 1) 23.8% of cells were Robo4 positive, whereas at a later time (day 11) the 
expression increased to 59.2% average. Secondly, we also compared the numbers of 
Robo4+ CD31+ cells at different time points. Maximal numbers of Robo4+ CD31+ cells 
were evident in samples collected at day 11 and day14 p.i (fig 2.2B). At this time point, 
levels of Slit2 protein were minimal and, as already mentioned, mRNA levels were also 
low in comparison to Robo4. We also attempted to sort endothelial cells from naïve 
uninfected and day 11 p.i. corneas (fig 2.2C&D). Accordingly, we could not sort any 
endothelial cells from naïve corneas but large numbers of endothelial cells were sorted 
from day 11 p.i. corneas (fig 2.2C&D). These sorted endothelial cells from day 11 p.i. 
corneas revealed the presence of Robo4 by WB (fig 2.2E). Additionally, the fact that 
blood vessel endothelial cells during SK expressed Robo4 was also demonstrable by 
confocal microscopy. Eyes taken from day 11 time point and subjected to confocal 
microscopy revealed endothelial cells with Robo4 receptors (fig 2.2F-H). Thus, taken 
together, our results could mean that although Robo4 is abundantly expressed by the new 
blood vessels that result from HSV infection, there may be an inadequacy of the ligand 
Slit2 to trigger an effective anti angiogenic response. 
Endogenous Slit2 is dispensable during SK. 
Additional experiments were performed to determine if the inhibition of Slit2 production 
in HSV infected animals had any effect on the extent of the ocular angiogenesis. To 
inhibit Slit2 expression, a lentiviral vector was used that expressed Slit2 shRNAs. Initial 
experiments in vitro using a MKT cell line expressing Slit2 (fig 2.3A) were performed to 
assess the efficacy of the lentivial knockdown system. The MKT cell line was transduced 
with lentiviruses expressing Slit2 shRNA/scrambled sequences. Fig 2.3B demonstrates 
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the average Slit2 gene expression values of two independent experiments. We could 
achieve around 55% reduction in Slit2 mRNA transcripts when Slit2 shRNAs were 
introduced into MKT cells compared to controls. We did not observe any Slit2 
knockdown using scrambled sequences, which confirmed in vitro knockdown of Slit2 
gene. In vivo experiments were done in HSV infected animals to determine if the 
lentiviral vector expressing Slit2 shRNAs had any effect on the extent of angiogenesis. 
The subconjunctival delivery (25) of lentiviruses encoding Slit2 shRNAs was started 
from day 1 post HSV infection with additional administrations on alternate days (fig 
2.3C). Corneas collected at day 9 revealed diminished Slit2 mRNA and protein compared 
to controls (fig 2.3D&E) suggesting a reduction in Slit2 mRNA and protein in vivo after 
lentiviral Slit2 shRNA administrations. However, when lentiviruses expressing Slit2 
shRNA treatment was further continued in another group of mice until day 11 and 
animals were observed at the end of the experiment (day 15) (fig 3F), no increase in 
angiogenesis or SK lesion severity was observed (fig 2.3G&H). These experiments were 
repeated three times, and the results suggest that endogenous Slit2 is dispensable during 
SK (due to low amounts). 
Provision of recombinant Slit2 diminishes angiogenesis and HSK. 
These experiments were carried out to observe the effect of subconjuctival Slit2 protein 
administration on HSV-1 induced angiogenesis. As shown in fig 2.4A, sub-conjunctival 
administration of Slit2 protein (starting from day 2 p.i. with additional doses on alternate 
days up to day 12) with different doses was done in mice and animals were examined at 
the end time of the experiment (day 15). This resulted in a dose dependent inhibition of 
angiogenesis with peak reduction achieved at the maximum dose of 1 &g Slit2 protein 
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when mice were examined at day 15 time point (fig 2.4B). Thus, preventive 
administration of Slit2 resulted in reduction in SK and angiogenesis scores (fig 2.4C-E). 
The eyes from the Slit2 treated group revealed reduction in visible angiogenesis 
compared to the mock treated group (figure 2.8A-C). The frequency and numbers of 
CD31+ endothelial cells (fig 2.4F&G), CD4+ T cells (fig 4H&I) and neutrophils (fig 
2.4J&K) were reduced in mice receiving Slit2 protein compared to mock treated animals. 
Curiously, even though the treatment of mice with Slit2 protein was delayed up to day 7 
post HSV-1 infection (with additional doses on alternate day until day 13), this treatment 
modality also resulted in diminished angiogenesis and SK lesion severity (day 15) (fig 
2.5A-C). Additionally, there was a reduction in the frequency and numbers of CD31+ 
endothelial cells (fig 2.5D&E), CD4+ T cells (fig 2.5F&G) and neutrophils (fig 2.5H&I) 
and in the Slit2 treated group. Additionally, when levels of various cytokines (IL1b, 
IFN", IL6 & Nos2) and chemokine’s (Cxcl1 & Cxcl2) were examined in Slit2/mock 
treated group, a reduction in the levels of different cytokines and chemokines was evident 
in Slit2 treated mice compared to infected controls at both day 11 and day 15 post 
infection (figure 2.8D&E). Taken together, our results demonstrate that Slit2 protein 
driven activation of endothelial Robo4 receptors can serve to modulate the extent of 
angiogenesis and subsequent immunopathology that occurs following HSV infection. 
Possible mechanism by which Slit2 exerts anti angiogenesis 
Blockade of Arf 6 and Rac 1 activity during HSK by Slit2 treatment  
Recent reports show that Slit2 inhibits angiogenesis by blockade of Arf 6 (19). GTP
ase 
activation assays for Arf 6 and Rac 1 were performed to see whether exogenously 
delivered Slit2 protein causes similar effects in an infectious disease setting. Mice 
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infected with ocular HSV-1 were provided with 1&g Slit2 protein subconjuctivly starting 
from day 2 with additional doses at day 4, day 6, day 8 and day 10. Active Arf 6 and Rac 
1 were pulled down from 6 corneas collected from each group at day 11 post infection 
(fig 2.6A). These were subjected to western blotting to determine levels of active Arf 6 
and Rac 1. As shown in fig 6B&C, total Arf 6 levels were similar in all groups, but there 
was an increase in GTP-Arf 6 in the case of mock treated animals compared to uninfected 
controls. In contrast, a reduction in GTP-Arf 6 in the Slit2 treatment group was observed 
indicating that Slit2 treatment resulted in the blockade of Arf 6 activity. Similar results 
were obtained in analyses from GTP-Rac 1 activation assays. There was an increase in 
GTP-Rac 1 in the mock treatment group over uninfected control animals but levels of 
GTP-Rac 1 were undetectable in the Slit2 treated group (fig 2.6D&E). Total Rac 1 
activity was similar in these groups. The above experiments were repeated two times. 
Additionally, the blood vessel endothelial cells (CD 31+) were sorted from mock/Slit2 
treated corneas at day 11 post infection (purity up to the extent of 85-90% was achieved) 
and active Arf 6 and Rac 1 were pooled down from the endothelial cells of the respective 
groups. As shown in figure 2.9A-E, levels of active Arf 6 and Rac 1 were lower in 
endothelial cells taken from Slit2 treated mice compared to mock while total Arf 6 and 
Rac 1 levels were similar in both groups. These experiments were repeated two times. 
These results indicate that the provision of excess Slit2 to HSV-1 infected mice reduces 
angiogenic Arf 6 and Rac 1 activity in the corneas. 
Slit2 may reduce anti apoptotic and cell cycle signal molecules in blood vessel 
endothelial cells 
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The observed reduced numbers and frequency of blood vessel endothelial cells in Slit2 
treated animals prompted us to investigate whether Slit2 treatments induced apoptosis of 
endothelial cells in vivo. To evaluate the situation in HSV infected ocular disease, 
infected mice were treated with 1 &g Slit2/ mock starting from day 2 up to day 10 on 
every alternate day and corneas collected at day 11 p.i were subjected to analysis (fig 
2.7A). The blood vessel endothelial cells (CD 31+) were sorted from mock/Slit2 treated 
corneas at day 11 (purity up to the extent of 90% was achieved) and analyzed for the 
expression of anti apoptotic Bcl-xL and cell cycle signal molecule Cyclin D1 by western 
blotting. As shown in fig 2.7B-E, levels of Bcl-xL and Cyclin D1 were down regulated in 
endothelial cells isolated from Slit2 treated mice compared to the mock treated group. 
These experiments were repeated two times. Additionally, these sorted blood vessel 
endothelial from both groups were subjected to WB and analyzed for the expression of 
active caspase 3 (indicating apoptosis). As shown in figure 2.10A-C, the level of caspase 
3 was higher in endothelial cells taken from Slit2 treated mice (indicating more 
apoptosis) compared to the mock treated group. The above experiments were repeated 
two times. The results of these experiments indicate that Slit2 treatments reduce anti 
apoptotic and cell cycle signal molecules while increase caspase 3 in blood vessel 
endothelial cells during SK. 
 
Discussion 
HSV ocular infection results in neovascularization of the normally avascular cornea. This 
represents a key event in the pathogenesis of a chronic inflammatory reaction in the eye 
(5-7, 9). In consequence, understanding how to control pathological angiogenesis is 
 9="
"
relevant since it could result in improved therapy of a lesion, stromal keratitis that is an 
important cause of human blindness. In the present report, we have evaluated if a host 
feedback anti-angiogenesis mechanism, namely the stimulation by Slit2 ligand of Robo4 
receptors on vascular endothelial cells, is operative in an infectious disease situation and 
to determine if manipulating the feedback system could represent a useful approach to 
constrain lesion severity. We demonstrate that Robo4 receptors are up regulated 
following HSV infection and that the majority of new blood vessel endothelial cells 
express Robo4. However, the expression levels of the Robo4 ligand, Slit2 were not 
significantly increased during the disease process. Moreover, the inhibition of Slit2 gene 
expression using lentiviral shRNAs had no effect on the extent of pathological 
angiogenesis. In contrast, providing additional Slit2 protein by subconjunctival 
administration resulted in significantly reduced angiogenesis. Mechanistically, the 
Slit2/Robo4 interaction was shown to block the downstream VEGF signaling molecules 
Arf 6 and Rac 1 and reduced the anti-apoptotic molecule Bcl-xL in blood vessel 
endothelial cells. Our results indicate that augmenting the host Robo4/Slit2 anti-
angiogenesis system could provide a useful therapeutic approach to control pathological 
angiogenesis associated with HSV induced stromal keratitis. 
Stromal keratitis remains a significant cause of vision impairment and new forms of 
therapy are needed. Controlling the extent of neovascularization, a key event in SK 
pathogenesis, represents a logical target for therapy. In animal models of SK, we and 
others have shown that reducing angiogenesis, as can be achieved by inhibiting the 
expression of angiogenic factors, results in milder lesions (6, 15, 16, 26). Similarly, 
angiogenesis is damaging to the retina and one treatment finding favor in the clinic is to 
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use the anti VEGF monoclonal antibody, bevacizumab (27, 28). Recently, it became 
apparent that the host itself has one or more systems that counteract the stimuli for new 
blood vessel development and malfunction. We chose to investigate the Slit2/Robo4 
system since this anti-angiogenic feedback mechanism was shown recently to influence 
vascular disease induced by trauma to the retina (18, 19). Moreover, both Slit2 and 
Robo4 can be artificially induced in the cornea by implants containing the angiogenic 
factor FGF (29). However, it was not known if the Slit2/Robo4 feedback mechanism had 
any regulatory effect in any natural infectious disease models where typically, as in SK, 
multiple angiogenic factors are involved in driving the pathological angiogenesis. 
Our results clearly show that the Robo4 up regulation becomes evident early after 
infection. We could show that the majority of the endothelial cells recovered from the 
neovascularized corneas expressed Robo4 receptors. Accordingly, the Robo4 mediated 
anti-angiogenesis system was poised to perform its regulatory function. Nevertheless, we 
advocate that this potential regulatory event may be inadequate during SK lesion 
pathogenesis since the ligand for Robo4, Slit2 was in limited supply. The reasons for this 
were not established, but they could relate to an inhibitory effect of virus on Slit2 gene 
expression which may be derived from corneal epithelial cells (29-32). This issue is 
currently under investigation. Following infection, a modestly increased expression of 
Slit2 did occur but this was considered as insignificant. Moreover, when Slit2 gene 
expression was reduced in the cornea, as was achieved using a lentivirus system that 
expressed shRNA for Slit2, an anticipated increase in the extent of pathological 
angiogenesis (20) was not observed. Accordingly, we must conclude that during the 
pathogenesis of HSV ocular lesions, the host Slit2/Robo4 anti-angiogenesis feedback 
 :%"
"
mechanism fails to influence the outcome of events. Nevertheless, we could also show 
that the anti-angiogenic system could be activated and play a modulatory effect on the 
virus induced angiogenesis. This was done by providing an additional supply of Slit2 
protein locally to the eye by subconjunctival injection. This procedure, which could be 
started as late as day 7 p.i resulted in significantly reduced angiogenesis and SK lesion 
severity compared to untreated controls. Additionally, we could observe a reduction in 
levels of various cytokines and chemokines in the corneas of Slit2 treated mice which is 
in line with recent findings of others (21). Our results support the observations of Jones et 
al (18, 19) using a non infectious vascular disease model in the retina that intravitreal 
administration of additional Slit2 protein can diminish vascular disease. 
Previous reports indicate that a number of biochemical events could explain the 
mechanisms by which Slit2 exerts its anti-angiogenic effect (18, 19, 33). These include 
activation of Robo4 receptors, which recruits paxillin and GIT 1 that in turn blocks 
angiogenic Arf 6 (VEGF downstream signaling) activity (18, 19). However, others 
suggest that Slit2 accelerates apoptosis in tumor systems by reducing the expression of 
the anti-apoptotic molecule Bcl-xL as well as diminishing cell cycle signal molecules 
such as Cyclin D 1 (33). Our results demonstrate that the Slit2 treatment in HSV infected 
mice resulted in significant reduction in Arf 6 and Rac 1 activity in corneas but the 
treatment modality also led to reduction in anti apoptotic Bcl-xL and cell cycle signal 
molecule Cyclin D1 while increased caspase 3 levels in blood vessel endothelial cells of 
Slit2 treated mice. Future studies are under investigation to determine whether blockade 
of downstream signaling molecules of VEGF such as Arf 6 or increasing cell cycle 
 :&"
"
inhibitors in blood vessel endothelial cells will lead to modulation of angiogenesis and 
SK.  
In conclusion, we have demonstrated that enhancing natural Slit2/Robo4 anti-angiogenic 
host feedback mechanism reduces virus induced angiogenesis and subsequent 
immunopathology. Here we show that the majority of the blood vessel endothelial cells 
recovered from the neovascularized corneas during SK expressed the Robo4 receptors. 
Nevertheless, the ligand Slit2, was found to be minimal leading to ineffectiveness of this 
natural feedback mechanism to control angiogenesis during this blinding 
immunopathology. Thus, the provision of additional amount of Slit2 protein led to 
significant reduction in angiogenesis and diminished immunopathology during SK. 
Accordingly, we advocate that manipulating the function of the host feedback mechanism 
holds promise as a potential approach for therapy of SK. 
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Appendix 
 
Figure 2.1. Expression of Robo4 and Slit2 after HSV infection. WT mice were 
sacrificed and 6 corneas were collected and pooled for mRNA analysis by RTPCR and 
for protein analysis by WB. (A) Agarose gel analysis of Robo4 (394 bp)(Lane 4) and 
Slit2 (465 bp) (Lane 6) transcripts from naive corneas (Pooled n=6 corneas). Lane M-
Marker, lane 2 is beta actin (325 bp). Lane 1, 3, and 5 are RT negative control for beta 
actin, Robo4 and Slit2 while lane 7 is negative control (water). Data are representative of 
three independent experiments. Reducing Western blot (WB) analysis of Robo4 (B) and 
Slit2 (C) protein in naïve corneas is shown. The kidney and brain were used as positive 
controls for Robo4 and Slit2 respectively. These experiments were repeated three times. 
WT mice were infected with HSV-1 RE in one eye and 6 corneas were collected and 
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pooled for analysis ether by QPCR or by WB. (D) Kinetic analysis of the expression of 
Robo4 mRNA levels shows peaks around day 7-day 14 p.i. Data are mean ± SEM 
(Pooled n=6 mice). (E) Quantification of Slit2 mRNA at different time points post HSV 
infection. Data are mean ± SEM (Pooled n=6 mice). (F) Reducing WB analysis of 
corneal samples from naive uninfected and day 9 p.i. reveals increase in Robo4 protein in 
infected corneas while slight change in Slit2 protein at day 9 p.i (Pooled n=6 mice). 
These experiments were repeated three times."
 
Figure 2.2. Robo4+ blood vessel endothelial cells in corneas after HSV infection. WT 
mice were infected with HSV-1 RE in one eye and 6 corneas were collected and pooled 
for analysis by flow cytometry. (A) Representative FACS plots from each time point 
show the percentage of Robo4+ blood vessel endothelial cells. Isotype controls are shown 
B 
!!!!!!!!!!! 
!!!!!!A 
!!!!!!!!!!! 
1  3 5  7  9 1
1
1
4
0
1000
2000
3000
4000
5000
Days Post Infection
N
o
. 
o
f 
R
o
b
o
4
+
C
D
3
1
+
ce
ll
s/
co
rn
ea
Day1                 Day3                  Day5                  Day7                  Day9                Day11             Day14  
!!!!!!!!!!!!!!!!!!!! 
     on  
CD 31+ 
    cells 
Robo4 
SSC 
!!!!!!!!!!!!!!!!!!!! 
CD31 
!!!!!!!!!!!!!!!!!!!! 
SSC 
!!!!!!!!!!!!!!!!!!!! 
CD31 
!!!!!!!!!!!!!!!!!!!! 
Naïve cornea 
(almost no CD31+ 
endothelial cells) 
Day 11 p.i corneas 
(Post sort CD31+ 
cells, 82% purity) 
Positive    
control, 
kidney 
Robo4 
!!!!!!!!!!!!!!!!!!!! 
Naive 
! actin !!43 kDa 
!!!!!!!!!!!!!!!!!!!! 
!!160 kDa 
!!!!!!!!!!!!!!!!!!!! 
Day 11 p.i. 
Endothelial 
cells 
CD 31 Robo4 Merge 
!!!!!F 
!!!!!!!!!!! 
!!!!!" 
!!!!!!!!!!! 
!!!!!!H 
!!!!!!!!!!! 
!!!!!!C 
!!!!!!!!!!! 
!!!!!!D 
!!!!!!!!!!! 
!!!!!!E 
!!!!!!!!!!! 
 ;%"
"
as faint grey lines. Data are representative of three independent experiments. (B) Total 
number of Robo4+ blood vessel endothelial cells per cornea at each time point post HSV-
1 infection reveals an increase in Robo4+ endothelial cells over time during SK with 
maximum number of cells observed at day 11 and day 14 p.i. Data are mean ± SEM 
(Pooled n=6 mice). These experiments were repeated three times. The sorting of CD31+ 
endothelial cells from naive uninfected mice (C) and day 11 p.i. corneas (D) is shown 
which reveals absence of endothelial cells in naive corneas while large number of 
endothelial cells were present in day 11 p.i. corneas. These sorted endothelial cells from 
HSV infected corneas were further subjected to WB to detect the presence of Robo4 (E) 
while kidney was used as a positive control for Robo4 detection. Representative 
immunofluorescence staining of endothelial cells sorted from day 11 p.i. corneas for 
blood vessel endothelial cells (green) (F), Robo4 (red) (G) and merge (Robo4+ 
endothelial cells) (H) reveals the presence of Robo4 on the blood vessel endothelial cells 
during SK. Single endothelial cell is shown. Image is the representative of two 
independent experiments. Original magnification x60. 
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Figure 2.3. Slit2 is dispensable during SK. (A) MKT cells expressing Slit2 mRNA 
transcripts. Agarose gel analysis of Slit2 (465 bp) (Lane 3) transcripts in MKT cells. Lane 
M-Marker, lane 1 is beta actin (325 bp). Lane 2 and lane 4 are RT negative control for 
beta actin and Slit2 respectively. Image is representative of three independent 
experiments. (B) Knockdown of Slit2 in MKT cells. Lentiviruses expressing Slit2 
shRNA/scrambled sequences were introduced into MKT cells and quantification of Slit2 
mRNA was carried out to evaluate Slit2 knockdown. One way ANOVA with 
Bonferroni’s post hoc test was used to calculate the level of significance. **P ( 0.01. 
These experiments were repeated three times. WT mice were infected with HSV-1 RE in 
one eye and 6 corneas were collected and pooled for analysis by QPCR or WB. (C) 
Lentiviruses expressing Slit2 shRNA/scrambled sequences were injected 
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subconjunctively in HSV infected mice as indicated. (D) Quantification of Slit2 mRNA 
from corneas isolated from different groups revealed knockdown of Slit2 mRNA in Slit2 
shRNA treatment group (Pooled n=6 mice/group). The level of significance was 
determined by student’s t test (unpaired). *P ( 0.05. These experiments were repeated 
three times. (E) Reducing WB for Slit2 protein after treatment of HSV infected mice with 
Slit2 shRNA/scrambled sequences (Pooled n=6 mice/group). WT mice were infected 
with HSV-1 RE in one eye and mice were monitored for the development of angiogenesis 
and SK up to day 15. (F) Lentiviruses expressing Slit2 shRNA/scrambled sequences were 
injected subconjunctively in HSV infected mice as indicated. HSK scores (G) and 
angiogenesis scores (H) at day 15 after the treatment of mice with either lentiviruses 
expressing Slit2 shRNAs/scrambled sequences. One way ANOVA with Bonferroni’s post 
hoc test was used to calculate the level of significance. No statistical significant 
differences among groups were observed. These experiments were repeated three times."
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Figure 2.4. Preventive administration of recombinant Slit2 protein diminishes 
angiogenesis and HSK. WT mice were infected with HSV-1 RE in one eye and 6 
corneas were collected and pooled for analysis by flow cytometry. (A) The Slit2/mock 
treatment was given to HSV infected mice as shown. (B) The dose dependent inhibition 
of angiogenesis scores after Slit2 treatment with maximum reduction in angiogenesis at 1 
&g Slit2 protein dose. These experiments were repeated two times. The Slit2 treatment 
regimen (C) resulted in reduction in HSK (D) and angiogenesis scores (E) in HSV 
infected animals. The frequency and total cell number per cornea for endothelial cells 
(CD31+ cells) (F & G), CD4+ T cells (H & I) and neutrophils (Gr1+, CD11b+ cells) (J & 
K) showed significant reduction in frequency and total cell number per cornea after 
preventive Slit2 treatment (Pooled n=6 mice/group). The level of significance was 
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determined by student’s t test (unpaired). **P ( 0.01, *P ( 0.05. These experiments were 
repeated two times. 
 
Figure 2.5. Provision of recombinant Slit2 protein therapeutically diminishes angiogenesis 
and HSK. WT mice were infected with HSV-1 RE in one eye and 6 corneas were collected and 
pooled for analysis by flow cytometry. The therapeutic Slit2 treatment (A) resulted in reduction 
in HSK (B) and angiogenesis (C) scores in HSV infected animals. The frequency and total cell 
number per cornea for endothelial cells (CD31+ cells) (D & E), CD4+ T cells (F & G) and 
neutrophils (Gr1+, CD11b+ cells) (H & I) showed significant reduction in total cell number per 
cornea after therapeutic Slit2 treatment (Pooled n=6 mice/group). The level of significance was 
determined by student’s t test (unpaired). **P ( 0.01, *P ( 0.05. These experiments were 
repeated two times. 
* 
* ** 
 0                           7         9           11      13    15 days p.i.!
HSV infection 
Slit2 (1µg) or Mock 
   !
Scoring 
M
o
ck
S
li
t2
0
2
4
6
H
S
K
 s
c
o
r
e
s
M
oc
k
Sl
it2
0
5
10
15
20
A
n
g
io
g
e
n
e
si
s 
sc
o
r
e
s
M
oc
k
Sl
it
2
0
2000
4000
6000
N
o
. 
o
f 
 C
D
3
1
+
 C
e
ll
s
 p
e
r
 C
o
r
n
e
a
M
o
ck
S
li
t2
0
2000
4000
6000
8000
N
o
. 
o
f
 C
D
4
+
T
 c
e
ll
s
/c
o
r
n
e
a
M
oc
k
Sl
it
2
0
50000
100000
150000
N
o
. 
o
f 
N
e
u
tr
o
p
h
il
s
 (
C
D
1
1
b
+
 G
r
1
+
 )
p
e
r
 C
o
r
n
e
a
SSC SSC 
CD31 CD4 
Gr1 
CD 11b 
Slit2 treated Slit2 treated 
Slit2 treated Mock treated Mock treated 
Mock treated 
    **     * 
!!!!!!A 
!!!!!!!!!!! 
!!!!!!B 
!!!!!!!!!!! 
!!!!!!C 
!!!!!!!!!!! 
!!!!!!D 
!!!!!!!!!!! 
!!!!!!E 
!!!!!!!!!!! 
!!!!!!F 
!!!!!!!!!!! 
!!!!!!G 
!!!!!!!!!!! 
!!!!!!H 
!!!!!!!!!!! 
!!!!!!I 
!!!!!!!!!!! 
 ;:"
"
 
Figure 2.6. Blockade of Arf 6 and Rac 1 activity after Slit2 treatment. WT mice were 
infected with HSV-1 RE in one eye and 6 corneas were collected and pooled for analysis by 
GTP
ase
 activation assays. (A) WT mice infected with HSV were treated with Slit2/mock as 
shown. The corneas collected at day 11 p.i. after Slit2/mock treatment were subjected to Arf 6 
(B&C) and Rac 1 (D&E) pull down followed by reducing WB analysis for Arf 6 and Rac 1 of 
the respective groups (Pooled n=6 mice/group). The results of two independent experiments are 
shown. 
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Figure 2.7. Slit2 may reduce anti apoptotic and cell cycle signal molecules in endothelial 
cells. WT mice were infected with HSV-1 RE in one eye and 6 corneas were collected and 
pooled for analysis by WB. The HSV infected mice were treated with Slit2/mock as shown (A) 
and CD 31+ cells were sorted from mock and Slit2 treated mice corneas. These sorted CD 31+ 
cells from respective groups were subjected to reducing WB for anti apoptotic molecule Bcl-xL 
(B&C) and cell cycle signal molecule cyclin D1 (D&E) (Pooled n=6 mice/group). The results of 
two independent experiments are shown."
!!43 kDa 
!!!!!!!!!!!!!!!!!!!! 
Mock             Slit2 
!!!!!!!!!!!!!!!!!!!! Cyclin D1 
!!!!!!!!!!!!!!!!!!!! 
! actin 
!!!!!!!!!!!!!!!!!!!! 
!!37 kDa 
!!!!!!!!!!!!!!!!!!!! 
     Mock          Slit2 
 !!!!!!!!!!!!!!!!!!! Bcl-xL 
!!!!!!!!!!!!!!!!!!!! 
! actin 
!!!!!!!!!!!!!!!!!!!! 
!!43 kDa 
!!!!!!!!!!!!!!!!!!!! 
!!30 kDa 
!!!!!!!!!!!!!!!!!!!! 
!!!!!!A 
!!!!!!!!!!! 
!!!!!!B 
!!!!!!!!!!! 
!!!!!!C 
!!!!!!!!!!! 
!!!!!!D 
!!!!!!!!!!! 
!!!!!!E 
!!!!!!!!!!! 
 0              2           4          6           8       10       11 days p.i. 
HSV infection 
Slit2 (1µg) or Mock 
   !
Sorting of CD 31+ cells  
from  corneas 
Mock          Slit2 
 !!!!!!!!!!!!!!!!!!! Bcl-xL 
!!!!!!!!!!!!!!!!!!!! 
! actin 
!!!!!!!!!!!!!!!!!!!! 
!!43 kDa 
!!!!!!!!!!!!!!!!!!!! 
!!30 kDa 
!!!!!!!!!!!!!!!!!!!! 
!!43 kDa 
!!!!!!!!!!!!!!!!!!!! 
   Mock              Slit2 
!!!!!!!!!!!!!!!!!!!! Cyclin D1 
!!!!!!!!!!!!!!!!!!!! 
! actin 
!!!!!!!!!!!!!!!!!!!! 
!!37 kDa 
!!!!!!!!!!!!!!!!!!!! 
 ;<"
"
 
Figure 2.8. Reduction in cytokine and chemokine levels after Slit2 treatment. WT mice were 
ocularly infected with 10
4 
PFU HSV-1 RE in one eye and monitored for the development of 
angiogenesis and SK. A) Slit2 or mock was administered at an indicated time points to these 
HSV infected mice. Representative eye photographs from (B) Slit2/mock (C) treated group at 
day 15 post HSV infection are shown. These experiments were repeated two times. The 
Slit2/mock treated mice were sacrificed at day 11 and day 15 p.i. and 6 corneas were collected 
and pooled for analysis by QPCR. Levels of various cytokines (IL1b, IFN", IL6 & Nos2) and 
chemokine’s (Cxcl1 & Cxcl2) in Slit2 (white bars)/mock (black bars) treated group at day 11 (D) 
and day 15 (E) p.i. are shown (Pooled n=6 mice/group). These experiments were repeated two 
times.   
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Figure 2.9. Slit2 inhibits Arf 6 and Rac 1 activity in endothelial cells during HSK. WT mice 
were infected with HSV-1 RE in one eye and 12 corneas were collected and pooled for analysis 
by WB. The HSV infected mice were treated with Slit2/mock as shown (A) and CD 31+ cells 
were sorted from mock and Slit2 treated mice corneas. These sorted CD 31+ cells from 
respective groups were subjected to Arf 6 (B&C) and Rac 1 (D&E) pull down followed by 
reducing WB analysis for Arf 6 and Rac 1 of the respective groups (Pooled n=12 mice/group). 
The results of two independent experiments are shown. 
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Figure 2.10. Increased caspase 3 activity in endothelial cells after Slit2 treatment. WT mice 
were infected with HSV-1 RE in one eye and 12 corneas were collected and pooled for analysis 
by WB. The HSV infected mice were treated with Slit2/mock as shown (A) and CD 31+ cells 
were sorted from mock and Slit2 treated mice corneas. These sorted CD 31+ cells from 
respective groups were subjected to WB for the analysis of active caspase 3 protein (B&C). The 
results of two independent experiments are shown (Pooled n=12 mice/group). 
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Part III 
 
Role of microRNA-132 in angiogenesis after ocular 
infection with herpes simplex virus 
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Research described in this chapter is reproduced from a publication accepted in American 
journal of pathology by Mulik S, Xu J, Reddy PB, Rajasagi NK, Gimenez F, Sharma S, 
Lu PY and Rouse BT. 
Mulik S, Xu J, Reddy PB, Rajasagi NK, Gimenez F, Sharma S, Lu PY, Rouse BT. Role 
of microRNA-132 in angiogenesis after ocular infection with herpes simplex virus. Am J 
Pathol. 2012 Aug; 181(2): 525-34. Reprinted from Am J Pathol 2012, 181:525-534 with 
permission from the American Society for Investigative Pathology.  
 
Abstract 
MicroRNAs (miRNAs) are small regulatory molecules that control diverse 
biological processes that include angiogenesis. Herpes simplex virus (HSV) infection of 
the eye may result in corneal neovascularization (CV) during blinding 
immunopathological lesion stromal keratitis (SK). miR-132 is a highly conserved 
miRNA which is induced in endothelial cells in response to growth factors. In this study, 
we show that miR-132 expression was up regulated (10-20 fold) after ocular infection 
with HSV an event that involved VEGF-A and IL-17 production. Thus, blocking VEGF-
A activity using soluble VEGF receptor 1 resulted in significantly lower corneal miR-132 
levels following HSV infection. Additionally, IL-17RKO mice revealed low levels of 
corneal miR-132 levels after HSV infection. In vivo silencing of miR-132 by the 
provision of anti miR-132 (antagomir-132) nanoparticles to HSV infected mice led to 
reduced CV and diminished SK lesions. The anti-angiogenic effect of antagomir-132 was 
reflected by reduction in angiogenic Ras activity in corneal CD31 enriched cells 
(presumably blood vessel endothelial cells) during SK. To our knowledge, this is one of 
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the first reports of miRNA involvement in an infectious ocular disease. Manipulating 
miRNA expression holds promise as a therapeutic approach to control an ocular lesion 
that is an important cause of human blindness. 
 
Introduction 
Herpes simplex virus (HSV) causes a chronic immuno-inflammatory response in 
the eye that is a significant cause of human blindness 
1
. The blinding lesion represents a T 
cell orchestrated reaction in the corneal stroma set off by the infection 
2
. These stromal 
keratitis (SK) lesions involve cellular and cytokine events that resemble those seen in 
some autoimmune diseases and control measures found effective in autoimmunity often 
similarly act to control SK. One major feature of SK that is not usually a prominent part 
of an autoimmune lesion is pathological angiogenesis 
3
. Thus the corneal site where SK 
occurs is normally an avascular tissue, which is a requisite for normal vision. Once 
corneal neovascularization (CV) has occurred, inflammatory cells can easily gain access 
to the eye, vision is impaired and blood vessels, once formed, are difficult to remove 
2
. 
Hence, a major objective of therapies to control SK and several other ocular lesions is to 
prevent or control the extent of neovascularization 
4
. Several approaches have been 
evaluated to achieve this objective but none have proven to be fully effective and 
alternative strategies are needed. Conceivably, controlling the expression of one or more 
species of microRNAs (miRNAs) is one such strategy. Thus several recent studies have 
indicated that miRNAs are exploitable gene regulators and many of them may be 
dysregulated during tissue damaging inflammatory reactions as well as during 
pathological angiogenesis 
5, 6
. Of particular interest miR-132 was shown to act as a switch 
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to activate embryonic human vascular endothelial cells to undergo vasculogenesis 
7
. The 
miR-132 was also upregulated during pathological angiogenesis in a tumor model and 
inhibiting miR-132 by antagomir nanoparticles was inhibitory to tumor angiogenesis 
7
. 
To date the role for miRNA in tissue damage and angiogenesis caused by an 
infectious agent is poorly understood. Some recent reports, however, have indicated that 
miRNA encoded by virus can play a role in the expression of latency 
8
, the induction of 
tumors 
9
 and may be involved in human cytomegalovirus immune evasion 
10
. We show 
herein that targeting miR-132 represents a potentially valuable approach for the control of 
the CV that occurs during SK. Accordingly, miR-132 expression is upregulated following 
infection and blockade of VEGF-A activity resulted in significantly lower corneal miR-
132 levels. Of particular interest, IL-17RKO mice produced less miR-132 in corneas after 
infection. Additionally, administration of antagomir-132 nanoparticles led to diminished 
angiogenic Ras activity that was reflected by significantly reduced angiogenesis and 
diminished SK lesions. The results of these studies indicate that manipulating miRNAs, 
as shown here by targeting miR-132, might provide an additional avenue for the control 
of an important cause of vision loss. 
 
Materials and methods 
Mice: Female 6-8 wks old C57 BL/6 mice were purchased from Harlan Sprague Dawley 
Inc. (Indianapolis, Indiana, USA). IL-17RKO mice on C57BL/6 background were 
obtained from Amgen (Thousand Oaks, CA). The animals were housed in American 
Association of Laboratory Animal Care-approved facilities at the University of 
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Tennessee Knoxville. All investigations followed guidelines of the institutional animal 
care and use committee.  
Virus: HSV-1 strain RE Tumpey was propagated in Vero cell monolayers (ATCC no: 
CCL81). Virus was grown in Vero cell monolayers (American Type Culture Collection, 
Manassas, VA), titrated, and stored in aliquots at –80˚C until used.  
Corneal HSV-1 infection and scoring: Corneal infections of mice were performed 
under deep anesthesia. The mice were lightly scarified on their corneas with a 27-gauge 
needle, and a 3 &l drop containing 10
4
 PFU of HSV-1 RE Tumpey was applied to one 
eye. The development of SK lesion severity and angiogenesis in the eyes of mice was 
examined by slit-lamp biomicroscopy (Kowa Company, Nagoya, Japan). The scoring 
system used was as follows: 0, normal cornea; 1, mild corneal haze; 2, moderate corneal 
opacity; 3, severe corneal opacity; 4, opaque cornea and ulcer; 5, corneal rupture. The 
severity of angiogenesis was recorded as described previously 
11
. According to this 
system, a grade of 4 for a given quadrant of the circle represents a centripetal growth of 
1.5 cm towards the corneal center. The score of the four quadrants of the eye were then 
summed to derive the neo vessel index (range 0-16) for each eye at a given time point. 
Sub-conjunctival injections: Sub-conjunctival injections were performed as reported 
previously 
12
. Briefly, these injections were carried out using a 2-cm, 32-gauge needle 
and syringe (Hamilton, Reno, NV) to penetrate the perivascular region of conjunctiva and 
appropriate amount of soluble VEGF receptor 1 protein/isotype or scrambled 
sequences/antagomir-132 nanoparticles was administered into sub-conjunctival space.  
Antagomir sequences: Anti miR-132 and scrambled sequences were procured from 
Ambion and used as reported previously 
7
.  
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Nanoparticle preparation: Optimized histidine-lysine polymers (HKP) have been 
applied for siRNA deliveries in vitro and in vivo 
13
. One HK polymer species, H3K4b, 
having a Lysine backbone with four branches containing multiple repeats of histidine and 
lysine, was used for packaging siRNAs against miR-132 or scrambled sequences with a 
nanoparticle to sequences ratio of 4:1 by mass. The nanoparticles (average size of 150 nm 
in diameter) were self-assembled and these HKP-siRNA nanoparticles were used in mice. 
Mice treatment with antagomir-132 nanoparticles: Mice ocularly infected with HSV-
1 RE Tumpey were separated into two groups. Antagomir-132 nanoparticle treatment 
was begun at day 2 with additional doses on alternate days until day 13 post infection. In 
another group of experiments, the antagomir-132 treatment was started at day 7 or day 10 
with additional doses on alternate days until day 13 post infection. Control group 
received nanoparticles containing scrambled sequences sub-conjunctively with the same 
regimen for respective experiments. These animals were carefully followed for the 
progression of angiogenesis and SK development. All experiments were repeated two 
times. 
Purification of CD31 enriched cells: Purification of CD31 enriched cells (presumably 
endothelial cells) from HSV infected corneas was carried out as described previously 
14
. 
Briefly, the excised corneas were pooled and digested with 60 U/ml Liberase for 35 
minutes at 37
0
C in a humidified atmosphere of 5% CO2. Single cell suspension was 
prepared and stained with anti CD31-FITC for 30 minutes on ice and FITC
+
 CD31
+ 
cells 
were sorted using a FACS sorter. Purity to an extent of 80-90% was achieved. These 
sorted CD31 enriched cells were used for pull down assays. 
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Flow Cytometry: Corneal single cell suspensions were prepared following Liberase 
digestion of corneas. These corneal cell suspensions were then stained for different cell 
surface molecules. Briefly, cell suspensions were incubated with CD45-allophycocyanin 
(30-F11), CD11b-PerCP (M1/79), Gr1-PE (1A8), CD 4-allophycocyanin (RM4.5) and 
CD31-FITC (BD Biosciences) for 30 minutes on ice. Thereafter, cells were washed three 
times and resuspended in 1% para-formaldehyde. Stained samples were acquired with a 
FACS Calibur (BD Biosciences) and the data were analyzed using the FlowJo software. 
Quantitative PCR (QPCR): Total mRNA was isolated from corneal cells using TRIzol 
LS reagent (Invitrogen, Carlsbad, California, USA). The cDNA prepared using 1 µg of 
RNA was used for subsequent analysis. QPCR was done using SYBR Green PCR Master 
Mix (Applied Biosystem, Foster City, CA, USA) with iQ5 real-time PCR detection 
system (Bio Rad, Hercules, CA, USA). The expression levels of the target genes were 
normalized to %-actin with 'Ct method and relative quantification between control and 
infected mice was performed using the 2
-''Ct
 formula. The primers used are as follows. 
RasGAPF 5’GAGAAGAAGATCCACACGAAGG3’ and 
RasGAPR 5’CTCCAGGAGTATTATCTGAGGG3’, %-actinF 5’CTACCTCATGAAGATCCTGACC3’ 
and %-actinR 5’GTCTAGAGCAACATAGCACAGC3’. 
TaqMan miRNA Quantitative PCR (TaqMan QPCR): The miRNAs were extracted 
from HSV infected mice corneas using mirVana™ miRNA Isolation Kit (Ambion, 
Austin, TX, USA). These extracted miRNAs were converted to cDNAs using TaqMan 
MicroRNA Reverse Transcription Kit (Applied Biosystems, USA) and primers for miR-
132 and miR-133a. TaqMan MicroRNA Assays (Applied Biosystems, USA) for miR-132 
and miR-133a were used to quantify these microRNAs using real-time PCR detection 
system (Applied Biosystems, USA). Data were normalized to the internal control small 
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nucleolar RNA 202. miR-133a (which is generally expressed in muscle cells) was used as 
a negative control for miRNA quantification from corneas 
15
. 
Neutrophil depletion with mAb: Depletion of neutrophils during SK was performed as 
described previously 
16, 17
. Mice ocularly infected with HSV-1 RE Tumpey were 
separated into two groups. One group of animals was administered with 200 µg of anti 
Ly6G mAb (1A8; BioXcell, West Lebanon, NH) intraperitoneally on alternate days 
starting from day 7 until day 13 post infection. Experiments were terminated on day 14 pi 
and corneal samples were collected for further analysis. Animals in control group were 
given isotype control (IgG2b) Ab (LTF-2; BioXcell) following the same regimen. These 
experiments were repeated two times. 
Western blot analysis: The corneal cells were lysed and total protein in the supernatants 
was quantified using BCA protein assay kit (Thermo scientific, Waltman, MA). Samples 
were denatured in Laemmli buffer and resolved by SDS-PAGE and proteins were 
transferred onto a PVDF membrane. The membrane was blocked with 5% BSA in Tris-
buffered saline with Tween 20 at 4
0
C overnight and subjected to incubation with specific 
primary and secondary antibodies. Proteins bands were visualized using 
chemiluminiscent HRP substrate (Millipore, Billerica, MA). After keeping in stripping 
buffer for 10 minutes, the membrane was re-probed using anti %-actin antibody. The 
antibodies used were as follows: mouse Ras (Thermo scientific, USA), anti %-actin (C4), 
anti Ras-GAP (B4F8), mouse anti VEGF-A (EE02), goat anti mouse IgG-HRP and 
donkey anti goat IgG-HRP (All these antibodies were procured from Santa Cruz 
biotechnology). 
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Ras
 
activation assay: Ras activation assays were carried out using Active Ras pull down 
and detection kit (Thermo scientific) according to manufacturer’s protocol. Briefly, resin 
slurry was added to the spin cup in a collection tube and 100 µg GST GGA3-PBD fusion 
protein with 800 µg total protein (corneal cell lysate) was added to this slurry. This was 
incubated at 4
o
C for 1 hour and finally 50 µl reducing sample buffer was added and GTP-
Ras was pulled down and subsequently analyzed by WB. These experiments were 
repeated two times. 
Viral plaque assay: Virus titers were measured in the eye swabs taken from HSV 
infected mice using plaque assays as described previously by others 
18
. 
Statistics: The statistical significance for SK lesion severity and angiogenesis between 
two groups was determined using unpaired two-tailed student's t test. One way ANOVA 
with Bonferroni’s post hoc test was used to calculate the level of significance for some 
experiments. P ( 0.001 (***), P ( 0.01 (**), P ( 0.05 (*) were considered as significant 
and results are expressed as mean ±SEM. For all statistical analysis, GraphPad Prism 
software was used. 
 
Results 
miR-132 is upregulated in mice corneas after ocular infection with herpes simplex 
virus 
To measure changes in miR-132 levels following ocular HSV infection, tissues 
were collected at various times and miRNAs quantified by QPCR. Changes in the levels 
of miR-132, but not control miR-133a, were evident by day 2 p.i. in infected samples 
with peak expression levels evident in day 7 and day 14 p.i. samples (figure 3.1A&B). 
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Uninfected scratch controls at the same time points showed no changes in the levels of 
miR-132 (data not shown). These data demonstrate that miR-132 expression is elevated 
at multiple time points after ocular HSV infection. 
Blockade of VEGF-A activity diminishes corneal miR-132 levels during SK 
The increased expression of miR-132 at time points when virus was cleared from 
the eyes and CV becomes quite evident (usually by day 7 p.i) raised the issue as to the 
triggers responsible for miR-132 upregulation. Since VEGF-A levels are increased 
following HSV infection and remain so throughout the disease syndrome 
17
, VEGF-A 
was suspected to be an agonist for miR-132 up-regulation. Moreover, VEGF-A can 
induce miR-132 expression in the human cell line HUVEC 
7
. To investigate the role for 
VEGF-A, we measured the effect of VEGF-A blockade on the expression of miR-132 
levels. To effect VEGF-A blockade, animals were treated after infection with 5&g VEGF 
trap (soluble VEGF receptor 1) or isotype control on alternate days starting from day 2 up 
to day 12 p.i.  These conditions were shown previously to markedly suppress VEGF-A 
protein activity and also to significantly inhibit CV 
17
. The corneas were collected at day 
7 and day 14 p.i and miR-132 levels were compared in isotype control and VEGF trap 
treated animals. When compared to uninfected scratch controls, the miR-132 levels were 
elevated at day 7 p.i. in isotype treated animals. However, miR-132 in the recipients of 
the VEGF trap were on average 4 fold less than in isotype treated animals (figure 3.2A). 
The same pattern was evident at day 14 p.i. in mice treated with VEGF trap compared to 
isotype treated animals (figure 3.2A). 
 In another set of experiments, neutrophils were depleted 
16
 during the clinical 
stage of SK (figure 3.2B). Neutrophils are a source of VEGF-A and their depletion results 
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in lower VEGF-A levels in corneas obtained from HSV infected mice 
17
. Depletion 
(using 200&g anti Ly6G antibody) was begun at day 7 p.i with additional doses on 
alternate days up to day 13. Neutrophil depletion was clearly evident in spleen and 
corneas of HSV infected mice treated with anti Ly6G antibody (figure 3.8A-C). 
Expression levels of miR-132 were compared in corneal pools from depleted and isotype 
control mice on day14 p.i. VEGF-A levels were reduced after depletion of neutrophils in 
these experiments (figure 3.2C). As shown in figure 3.2D, miR-132 expression levels 
were reduced by on average 3 fold in the neutrophil depleted mice compared to isotype 
treated animals. Taken together the two approaches support the notion that VEGF-A 
could be responsible for the upregulation of miR-132 expression during HSV induced 
CV. 
Diminished levels of miR-132 in IL-17RKO mice after HSV infection 
Our recent observations that mice unable to respond to IL-17A showed reduced 
corneal VEGF-A levels 
19
 led us to investigate the possible role of IL-17A on miR-132 
expression after HSV infection. To this end, IL-17A receptor knockout (IL-17RKO) mice 
or WT mice were infected with HSV and miR-132 levels were measured at day 2, 7 and 
14 p.i while Ras-GAP levels (miR-132 target) were measured at day 7 p.i. The significant 
increase in the levels of Ras-GAP was evident in IL-17RKO mice (figure 3.2E). As 
shown in figure 3.2F&G, IL-17RKO mice showed reduced CV and SK lesions compared 
to WT animals. Additionally, when miR-132 levels were measured in the infected 
corneas at day 7 and 14 p.i, IL-17RKO mice showed two fold reduction in miR-132 
levels compared to WT mice (figure 3.2H). The results from these experiments indicate 
that the cytokine IL-17A is involved in miR-132 upregulation after HSV infection. 
 =&"
"
In vivo silencing of miR-132 by antagomir-132 nanoparticles reduces angiogenic Ras 
1 in corneas 
Experiments were done using nanoparticles containing an antagomir for miR-132 
or scrambled sequences to determine the effect of antagomir treatment on miR-132 levels 
in post infection corneas. A dose of 2.5&g antagomir-132 provided significant miR-132 
knock down when measured at day 7 p.i (fig 3.3A&B). Since miR-132 targets RasGAP 
mRNA 
7
, levels of both RasGAP mRNA and protein were measured. These were 
elevated in mice treated with antagomir-132 nanoparticles compared to scrambled 
sequence recipients (fig 3.3C&D).  
Additional experiments were performed to measure expression of active Ras 1 
following in vivo knockdown in infected animals, since miR-132 promotes VEGF 
signaling by influencing active Ras levels in HUVEC cells 
7
. Mice infected with HSV 
were given 2.5&g antagomir-132, or scrambled sequences, subconjuctivaly starting from 
day 2 p.i with additional doses on alternate days until day 10 p.i. Active Ras 1 was pulled 
down from 6 corneas collected from each group at day 11 p.i (figure 3.4A). As shown in 
figure 4B&C, total Ras 1 levels were similar in all groups, but an increase in GTP-Ras 1 
was evident in animals treated with scrambled sequences compared to uninfected 
controls. In contrast, a reduction in GTP-Ras 1 was observed in the antagomir-132 
treatment group. Additionally, active Ras 1 pulled down from the CD31 enriched cells 
(presumably blood vessel endothelial cells) sorted from scrambled sequences or 
antagomir-132 treated mice corneas at day 11 p.i, revealed reduction in active Ras 1 in 
antagomir-132 treated mice (figure 3.9D&E). Curiously there was no difference in 
VEGF-A levels between these groups (figure 3.4D&E). Collectively, these results 
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indicate that the provision of antagomir-132 to HSV-1 infected mice reduces the 
angiogenic Ras 1 activity but does not affect VEGF-A levels in the corneas. 
Provision of antagomir-132 nanoparticles diminishes corneal neovascularization 
To evaluate the effect of inhibiting miR-132 expression on the extent of 
angiogenesis induced following infection, animals were given an optimal dose 
subconjunctivally of antagomir-132, or control nanoparticles, either starting treatment at 
day 2 or day 7. As shown in fig 3.5A-C, treatment begun on day 2 resulted in 
significantly reduced CV in the antagomir treated animals and SK severity was also 
significantly reduced. Visible reduction in angiogenesis was evident in eyes of mice 
treated with antagomir-132 (figure 3.9A-C). Examination of collagen digested corneas at 
the termination of experiments on day 14 revealed that inflammatory cells were 
significantly diminished in numbers in the antagomir-132 treated group (fig 3.5D-I). We 
also measured the ocular viral titers on day 5 p.i. after administration of antagomir-132 or 
scrambled sequences and slight increase in viral levels was evident in antagomir-132 
treated animals (figure 3.10A&B). 
In the experiments where treatment was begun on day 7 p.i. significantly 
diminished angiogenesis was also evident in the antagomir-132 treated animals (figure 
3.6A-C). At the end of experiments on day 14, subpools of corneal collagen digests were 
analyzed by flow cytometry to enumerate the numbers of the CD31
+
 cells (a marker for 
vascular endothelial cells) as well as Gr1+CD11b+ cells (figure 3.6D-G). Both cell 
populations were significantly reduced in number in the recipients of antagomir-132 
compared to those that received the scrambles sequence nanoparticles. In addition, the 
infiltration of CD4
+
 T cells was reduced in antagomir-132 treated animals compared to 
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scrambled sequence controls (figure 3.6H&I). Curiously, even when antagomir-132 
treatment was started as late as day 10 p.i. (after establishment of blood vessels in eyes), 
this treatment modality resulted in reduction in corneal neovascularization (figure 3.10C-
E) but these changes were not statistically significant. Taken together, our results 
demonstrate that the silencing of miR-132 in the HSV infected eyes modulates the extent 
of angiogenesis and the subsequent immunopathology that occurs following HSV 
infection. 
 
Discussion 
Ocular HSV infection results in corneal neovascularization (CV) in the normally 
avascular cornea. This represents a key event in the pathogenesis of a chronic 
inflammatory lesion in the eye that impairs vision. In consequence, understanding how to 
control pathological angiogenesis is a significant therapeutic objective. Recently, it has 
become evident that the process of neovascularization in tumors is influenced by a 
number of miRNAs, particularly miR-132, that act to control the response of vascular 
endothelial cells to angiogenic factors such as VEGF-A. We have evaluated the role of 
miR-132 in an infectious disease model involving angiogenesis that represents an 
important cause of human blindness. We show that miR-132 is upregulated in the corneas 
soon after infection with levels remaining elevated throughout the chronic inflammatory 
reaction caused by the infection. Of notable interest, the extent of CV could be 
significantly diminished by local administration to the eye of nanoparticles containing 
antagomirs that blunted the miR-132 response. Furthermore, inhibition of CV could still 
be achieved when the therapy was begun 7 days p.i, a time when CV was underway, the 
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chronic inflammatory reaction clinically evident and replicating virus infection no longer 
present in the eye. However, inhibition of CV was not complete after antagomir-132 
treatment and it is possible that using additional approaches along with antagomirs might 
be more successful. One critical event influenced by miR-132 was the response of 
VEGFR2 expressing vascular endothelial cells to VEGF-A as was recently described by 
the Cheresh group 
7
. MiR-132 was shown to target Ras-GAP, an endogenous inhibitor of 
Ras, which when activated is responsible for causing vascular endothelial cells to 
proliferate. In agreement with these observations, we could show in our study that the 
administration miR-132 antagomirs diminished Ras activity in the CD31 enriched cells 
(presumably blood vessel endothelial cells). Our results indicate that modulating miRNA 
represents an effective approach to control CV which reflects in reducing the severity of 
SK lesions caused by HSV infection. The results are summarized in figure 3.7. 
 MiRNAs are becoming well known as regulators of immunity and inflammation 
and manipulating their expression holds promise as a therapeutic maneuver 
20
. Few 
studies to date have focused on the relevance of miRNA in the control of pathological 
angiogenesis. However, it is becoming evident that levels of several miRNA species are 
changed during tumor angiogenesis which to date have been the systems mainly 
investigated. The miRNA with changed expression include miR-132, miR-20a, miR-21 
and miR-106a 
5
. Recently, the Cheresh group drew attention to a likely major role for 
miR-132 during angiogenesis since miRNA screens of embryonic vascular endothelial 
cell (HUVEC) responses to VEGF-A stimulation, revealed that miR-132 expression was 
the most elevated 
7
. Moreover, they could show that normal expression of miR-132 was 
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necessary for vascular development and that preventing its upregulation was beneficial in 
a tumor angiogenesis system.  
Apart from effects of miR-132 on angiogenesis, the miRNA may also influence 
aspects of neural function, which has been reported to occur in some other systems 
21-23
. 
Since the pathogenesis of HSV often involves stress related effects on a latent infection in 
the nervous system, it is conceivable that regulation by miR-132 is involved in this 
process. This issue merits further investigation.  
In addition, rapid responses to some viruses, that include HSV, may induce miR-
132 
24
, although such responses are likely to represent innate reactions to the virus rather 
than being responses to virus gene expression. In line with this LPS, a TLR-4 ligand, may 
also cause the rapid expression of miR-132 in macrophages in vitro 
22
. In our studies, we 
noted early upregulation (by 48 hr pi) of miR-132 which might represent a response to 
the well characterized TLR ligand activity of HSV 
25, 26
.  Preliminary unpublished in vitro 
experiments support this interpretation and our past observations that TLR-2 and TLR-9 
knockout mice have diminished CV compared to wild type animals is in line with the 
same interpretation
18
.  
 There are reasons, however, to consider that the direct binding effects by virus to 
cells may not be the major stimulus for miR-132 production, particularly by vascular 
endothelial cells. Accordingly, in the mouse model, virus replication is usually confined 
to the corneal epithelium, but neovascularization occurs in the underlying stroma 
2
. Since 
miRNAs exert regulatory effects only in cells that produce them, any effect of infection is 
expected to be mediated indirectly via soluble molecules, such as cytokines and cell 
breakdown products, generated during the course of infection. Our data, along with the 
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published report of others 
7
, indicate that one agonist responsible for causing miR-132 
production in vascular endothelial cells was VEGF-A. Evidence for this conclusion came 
from in vivo observations that procedures that caused diminished VEGF-A production or 
activity resulted in reduced levels of miR-132. For example, lowering VEGF-A levels by 
a VEGF trap approach, or reducing the presence of some cell types such as neutrophils 
that produce VEGF-A, resulted in diminished miR-132 levels. Perhaps more convincing 
in favor of VEGF-A as responsible for miR-132 production, we showed that animals 
treated with nanoparticles containing miR-132 antagomirs had reduced levels of 
downstream signaling products of VEGF-A stimulation such as active Ras in the CD31 
enriched cells (presumably blood vessel endothelial cells) than controls (figure 7). 
An unsolved issue, however, is to explain the connection between the virus 
infection and the VEGF-A production. Some have advocated that virus infected cells 
themselves produce VEGF-A 
27
, but perhaps the more common circumstance is VEGF-A 
production by several uninfected cell types in response to one or more agonists generated 
as a consequence of the infection. These agonists include proinflammatory cytokines 
such as IL-6 that we showed in previous study can cause inflammatory cell types to 
produce VEGF-A 
28
. An additional cytokine that could participate in causing VEGF-A 
production is IL-17A. This cytokine is produced in the cornea after HSV infection mainly 
by innate immune cells in initial stages and later on by CD4 Th17 T cells 
29
. In support of 
IL-17A as involved in miR-132 production, we showed that levels of miR-132 produced 
in WT mice after infection were higher than those in animals unable to respond to IL-
17A because they lacked the IL-17A receptor. Accordingly, IL-17RKO animals 
displayed more miR-132 target, Ras-GAP in corneas after HSV infection. 
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Our observation that miR-132 appears involved in orchestrating CV in an 
infectious disease situation is a novel finding.  It leads to the question as to the 
therapeutic potential of targeting miRNAs as a means to control clinical 
diseases.  Progress on this topic has already been accomplished in some autoimmune and 
neoplastic diseases 
30
. Many studies focus on miR-155 that is involved in regulating 
inflammatory pathways 
31
.  MiR-155 can be upregulated by exposure to several TLR 
ligands and is over-expressed during some autoimmune diseases as well as a diverse 
array of immune cell cancers 
20
. Of particular interest, knockout mice exist that lack miR-
155. Such mice are resistant to experimental autoimmune encephalomyelitis and collagen 
induced arthritis and generate T cell responses that emphasize the Th2 pattern 
32
.  In 
preliminary studies, we have shown that miR-155 may also be involved in the 
pathogenesis of SK (unpublished results).  In disease situations that involve changes in 
one or more species of miRNAs, the issue will be to determine if modulating their 
expression represents a more viable approach to control inflammatory and 
neoplastic diseases than other procedures.  We are attempting to answer this question in 
the SK system by comparing the miRNA antagomirs in nanoparticles approach with other 
control procedures.  So far there are no results to report. Whatever occurs, there is at least 
one theoretical advantage of targeting miR-132 to control angiogenesis. Thus, anti-
angiogenic therapies that target single pathways such as VEGFR signaling often develop 
resistance by upregulating alternative angiogenic growth factors 
33
. This problem can be 
avoided using miR-132 since it removes an endogenous regulator (RasGAP) involved in 
controlling responses to several angiogenic factors. On the other hand, since 
miRNAs have multiple mRNA targets, a potential downside of the approach could be a 
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crossfire effect that turns off some useful gene expression alongside that of the gene 
being selected for silencing.  The results of future studies will reveal when situations are 
most appropriate for the use of miRNA for therapy.  
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Appendix 
 
Figure 3.1. Expression of miR-132 after HSV infection. miRNA quantification in HSV 
infected mice corneas: WT mice were infected with HSV-1 RE in one eye and 6 corneas 
were collected and pooled for miRNA analysis by TaqMan QPCR. The expression levels 
of miR-132 (A and miR-133a (B) at different time points post HSV infection in mice 
corneas are shown (Pooled n=6 mice/group). One way ANOVA with Bonferroni’s post 
hoc test was used to calculate the level of significance. P ( 0.01 (**), P ( 0.05 (*). Error 
bars represent means ± SEM. The above experiments were repeated three times. 
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Figure 3.2. IL-17A and VEGF-A upregulates miR-132 in corneas. WT mice were 
infected with HSV-1 RE in one eye and 6 corneas were collected and pooled for miR-132 
analysis by TaqMan QPCR. The 5 &g soluble VEGFR1/isotype treatment was begun on 
day 2 p.i with additional doses on alternate days until day 6 and and miR-132 
quantification was carried out at day 7 p.i (Pooled n=6 mice/group). In another set of 
experiments, 5 &g soluble VEGFR1/isotype treatment was continued up to day 12 p.i and 
corneas were analyzed for miR-132 expression at day 14 p.i (A) (Pooled n=6 
mice/group). One way ANOVA with Bonferroni’s post hoc test was used to calculate the 
level of significance. P ( 0.05 (*). Error bars represent means ± SEM. Neutrophil 
depletion was carried out using anti Ly6G antibody as shown (B). The HSV infected 
mice were treated with 200 &g of anti Ly6G/isotype antibody as shown and corneas were 
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analyzed for VEGF-A levels by western blotting and for miR-132 expression by QPCR at 
day 14 p.i (C&D) (Pooled n=6 mice/group). The level of significance was determined by 
student’s t test (unpaired). P ( 0.01 (**), P ( 0.05 (*). WT and IL-17RKO mice were 
infected with HSV-1 RE in one eye and 6 corneas were collected and pooled for Ras-
GAP mRNA analysis at day 7 p.i (E) and miR-132 analysis by TaqMan QPCR at day 14 
p.i. SK lesions (F), angiogenesis scores (G) and miR-132 expression (H) in HSV infected 
IL-17RKO mice and WT mice at day 2, 7 and 14 p.i. are shown. (Pooled n=6 
mice/group). Error bars represent means ± SEM. All experiments were repeated two 
times. 
 
Figure 3.3. Knockdown of miR-132 by antagomir-132 nanoparticles in eyes. (A) The 
different doses of antagomir-132/scrambled sequences nanoparticle treatment was given to HSV 
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infected mice as shown. The 2.5&g antagomir-132 treatment regimen resulted in peak miR-132 
knockdown in the corneas (B) (Pooled n=6 mice/group). One way ANOVA with Bonferroni’s 
post hoc test was used to calculate the level of significance. P ( 0.05 (*). These experiments 
were repeated two times. WT mice were infected with HSV-1 RE in one eye and 6 corneas were 
collected and pooled for analysis by QPCR or WB. The 2.5&g antagomir-132/scrambled 
sequences were injected subconjunctively in HSV infected mice and the quantification of 
RasGAP mRNA (C) from corneas isolated from different groups was carried out (Pooled n=6 
mice/group). The level of significance was determined by student’s t test (unpaired). ***P ( 
0.001. These experiments were repeated two times. Error bars represent means ± SEM. Reducing 
WB for Ras-GAP protein after treatment of HSV infected mice with 2.5&g antagomir-
132/scrambled sequences (D) (Pooled n=6 mice/group). The representative WB image of two 
independent experiments is shown. 
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Figure 3.4. Reduction in angiogenic Ras activity after antagomir-132 treatment. WT mice 
were infected with HSV-1 RE in one eye and 6 corneas were collected and pooled for analysis 
by GTP
ase
 activation assays. (A) WT mice infected with HSV were treated with antagomir-
132/scrambled sequences nanoparticle as shown. The corneas collected at day 11 p.i. after 
antagomir-132/scrambled sequences nanoparticle treatment were subjected to Ras (B&C) pull 
down followed by reducing WB analysis for Ras of the respective groups (Pooled n=6 
mice/group). The representative WB image is shown. The corneas collected at day 11 p.i. after 
antagomir-132/scrambled sequences nanoparticle treatments were subjected to WB for the 
detection of VEGF (D&E). The representative WB image is shown. These experiments were 
repeated two times and densitometry analysis of the band strength is shown. One way ANOVA 
with Bonferroni’s post hoc test was used to calculate the level of significance. P ( 0.001 (***). 
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Error bars represent means ± SEM. 
 
Figure 3.5. Preventive administration of antagomir-132 diminishes angiogenesis and 
SK. WT mice were infected with HSV-1 RE in one eye and 6 corneas were collected and 
pooled for analysis by flow cytometry. (A) The 2.5&g antagomir-132/scrambled 
sequences nanoparticle treatment was given to HSV infected mice as shown. The 
antagomir-132 treatment regimen resulted in reduction in SK (B) and angiogenesis scores 
(C) in HSV infected animals. The frequency and total cell number per cornea for 
endothelial cells (CD31
+
 cells) (D & E), Gr1
+
, CD11b
+
 cells (presumably neutrophils) (F 
& G) and CD4
+
 T cells (H & I) showed significant reduction in frequency and total cell 
number per cornea after preventive antagomir-132 treatment (n=6-8 mice/group). The 
level of significance was determined by student’s t test (unpaired). P ( 0.01 (**), P ( 0.05 
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(*). Error bars represent means ± SEM. These experiments were repeated two times. 
 
Figure 3.6. Provision of antagomir-132 nanoparticles therapeutically diminishes 
angiogenesis and SK. WT mice were infected with HSV-1 RE in one eye and 6 corneas 
were collected and pooled for analysis by flow cytometry. The therapeutic 2.5&g 
antagomir-132 nanoparticles treatment (A) resulted in reduction in SK (B) and 
angiogenesis (C) scores in HSV infected animals. The frequency and total cell number 
per cornea for endothelial cells (CD31
+
 cells) (D & E), Gr1
+
, CD11b
+
 cells (F & G) and 
CD4+ T cells (H & I) showed significant reduction in total cell number per cornea after 
therapeutic antagomir-132 nanoparticle treatment (n=12-18 mice/group). The level of 
significance was determined by student’s t test (unpaired). P ( 0.01 (**), P ( 0.05 (*). 
Error bars represent means ± SEM. These experiments were repeated two times. 
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Figure 3.7. Illustration of antagomir-132 mediated inhibition of corneal 
neovascularization (CV). Left panel describes outcome (CV) in HSV infected untreated 
mice: HSV infection leads to upregulation of IL-17 in corneas. IL-17 (along with IL-6 
and virus infected epithelial cells) increases VEGF (probably via increasing IL-1b, IL-6 
and Cxcl1) levels in the eyes. VEGF thus acting through VEGFR2 receptors on the blood 
vessel endothelial cells upregulates miR-132 expression via CREB transcription factor. 
MiR-132 removes RasGAP (intrinsic inhibitor of Ras) leading to activation of Ras and 
CV. Right panel describes modulation of CV by miR-132 silencing: Administration of 
antagomir-132 nanoparticles leads to deposition of antagomir-132 cargo in blood vessel 
endothelial cells resulting in silencing of miR-132. This leads to higher levels of 
RasGAP, which thereby inhibits angiogenic Ras activity resulting in inhibition of CV. 
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Figure 3.8. Neutrophil depletion after anti Ly6G antibody treatment in mice. 
Neutrophil depletion was carried out using anti Ly6G antibody as shown (A). The HSV 
infected mice were treated with 200 &g of anti Ly6G/isotype antibody as shown and 
corneas (B) and spleen (C) were analyzed for the presence of Ly6G+ CD11b+ cells. 
Representative FACS plots from both groups are shown (n=5 mice/group). 
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Figure 3.9. Antagomir-132 reduces CV and endothelial Ras activity in corneas after 
HSV infection. WT mice were infected with HSV-1 RE in one eye and monitored for the 
development of angiogenesis and SK. The therapeutic 2.5&g antagomir-132 nanoparticles 
treatment (A) resulted in visible reduction in angiogenesis in antagomir-132 treated 
animals (B) compared to mice treated with scrambled sequences (C). The HSV infected 
mice were treated with antagomir-132/scrambled sequences nanoparticle as shown (D) 
and CD31
 
enriched
 
cells were sorted from antagomir-132/scrambled sequences 
nanoparticle treated mice corneas. The purity up to the extent of 80-90% was achieved. 
These CD31
 
enriched
 
cells from respective groups were subjected to Ras (E) pull down 
followed by reducing WB analysis for Ras of the respective groups (Pooled n=12 
mice/group). The representative WB image of the two independent experiments is shown. 
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Figure 3.10. Late antagomir-132 treatment slightly diminishes angiogenesis and SK. 
WT mice were infected with HSV-1 RE in one eye. The 2.5&g antagomir-132/scrambled 
sequences nanoparticle treatment was given to HSV infected mice as shown (A). The 
antagomir-132 treatment regimen resulted in slight reduction in SK (B) and angiogenesis 
scores (C) in HSV infected animals but these changes were not significant. The level of 
significance was determined by student’s t test (unpaired). P ( 0.05 (*). These 
experiments were repeated two times. 
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Part IV 
MicroRNA-155: Regulator of HSV-1 encephalitis but 
promotes stromal keratitis 
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Abstract 
Herpes simplex virus (HSV) infection of humans can lead to life threatening herpes 
simplex encephalitis (HSE) and sometimes blinding ocular lesion, stromal keratitis (SK). 
Here, we show that mice with a deficiency of miR-155 are highly susceptible to HSE 
with a majority of mice (75-80%) dyeing after ocular infection with HSV. Acyclovir 
treatment (a day after virus reaches brain) reduced brain viral levels and protected miR-
155 knockout mice from HSE thus supporting the role for virus replication in brain as the 
cause of encephalitis. Furthermore, HSV infected miR-155 deficient mice developed 
compromised virus specific CD8 T cell responses. Additionally, miR-155KO survivors 
developed attenuated HSK lesions in eyes. This phenotype was also evident after 
knockdown of miR-155 in WT mice. miR-155 deficiency demonstrated diminished Th1 
responses in corneas and lymphoid organs accompanied by a profound reduction in 
inflammatory and angiogenic molecules in corneas. Furthermore, combinatorial blockade 
of miR-132 and miR-155 led to potent reduction in ocular immunopathology. In 
conclusion, we have discovered dual role for miR-155, a regulator of HSV encephalitis 
but an enhancer of HSK.  
 
Introduction 
Herpes simplex virus infection generally causes mucocutaneous disease at oral and 
genital surfaces. In some instances, HSV can induce lesions in the eyes leading to 
blinding disease, stromal keratitis (SK)(Giménez, Suryawanshi et al. 2012) and due to its 
neurotrophic nature HSV can also invade brain. HSV-1 is a major cause of encephalitis, 
which is primarily controlled by IFNs, NK cells and CD8 T cells. MicroRNAs are small 
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RNAs that regulate gene expression post transcriptionally(Lee, Feinbaum et al. 1993; 
O'Connell, Rao et al. 2010). Whether miRNAs play any role in regulating herpes simplex 
encephalitis (HSE) is currently unknown. ?!3@%99" A4+!B!#*/1" -*C5/,B*+"
!0D/,??,B!40EFGH400*//I" 3,4" *B" ,/6" &>%&JI" !+" -*K5!-*(" D4-" 04-?,/" !??50*"
D50LB!40E34(-!C5*MI" N!C4-!B4" *B" ,/6" &>>;O" 2),!I" H,/,(4" *B" ,/6" &>>;JI" !+" !0#4/#*(" !0"
C*0*-,B!40"4D"A,B)4C*0!L"2"L*//+EFGH400*//I"P,)0"*B",/6"&>%>J",0(",/+4"D50LB!40+",+"
,0"40L4?!-" !0"#,-!45+"L,0L*-+EQ!,0CI"R),0C"*B",/6"&>%>J6"S0!?,/+"(*D!L!*0B" !0"?!3@
%99" T*L,5+*" 4D" C*0*" U04LU45B" EPFJ" ,-*" -*+!+B,0B" B4" B)*" !0(5LB!40" 4D" +4?*"
,5B4!??50*"(!+*,+*+E./V?/I".40*//!"*B",/6"&>%%O"P5-4W+U,@'B4/,-+U,I"S/!#*-0!0!"*B"
,/6" &>%%J6" In this report, we show that miR-155 deficiency leads to increased 
susceptibility of mice to HSV-1 encephalitis with majority of mice dyeing of 
encephalitis. miR-155 null mice also demonstrated attenuated HSV specific CD8 T cell 
responses in peripheral lymphoid organs. Additionally, miR-155 deficiency leads to 
resistance to HSK. Thus, miR-155 protects brain from HSE but increases ocular 
immunopathology after ocular HSV infection. 
 
Methods 
Mice: Female 6-8 wks old C57 BL/6 mice were purchased from Harlan Sprague Dawley 
Inc. (Indianapolis, Indiana, USA). miR-155KO mice on a C57BL/6 background were 
obtained from Jackson laboratories. The animals were housed in American Association of 
Laboratory Animal Care-approved facilities at the University of Tennessee Knoxville. 
All investigations followed guidelines of the institutional animal care and use committee.  
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Virus: HSV-1 strain RE was propagated in Vero cell monolayers (ATCC no: CCL81). 
Virus was grown in Vero cell monolayers (American Type Culture Collection, Manassas, 
VA), titrated, and stored in aliquots at –80˚C until used.  
Corneal HSV-1 infection and scoring: Corneal infections of mice were performed 
under deep anesthesia. The mice were lightly scarified on their corneas with a 27-gauge 
needle, and a 3 &l drop containing 10
4
 PFU of HSV-1 RE was applied to one eye. These 
mice were monitored for the development of encephalitis. The SK lesion severity and 
angiogenesis in the eyes of mice were examined by slit-lamp biomicroscopy (Kowa 
Company, Nagoya, Japan) as described previously(Rajasagi, Reddy et al. 2011). 
Purification of astrocytes and microglia: Purification of astrocytes from < day 8 
neonatal brains of WT and miR-155 deficient mice was carried out as per manufacturers 
guidelines (Miltenyl Biotech). The purity to the extent of 90-95% was achieved in these 
experiments and astrocytes were infected with HSV as described previously (Reinert, 
Harder et al. 2012) and virus was quantified in the supernatant. For microglia isolation, 
adult WT and miR-155 null mice brains were used. The microglial cells were stimulated 
with TLR-2 ligand, TLR-4 ligand and HSV and inflammatory cytokines and chemokines 
were measured.  
Flow Cytometry: Single cell suspensions were prepared from cornea, cervical DLN, and 
spleen of mice at different time points pi. The single cell suspensions obtained from 
corneas, DLN, and spleen were stained for different cell surface molecules for FACS. All 
steps were performed at 4°C. A total of 1)10
6
 cells were first blocked with an 
unconjugated anti-CD32/CD16 mAb for 30 min in FACS buffer. After washing with 
FACS buffer, fluorochrome-labeled respective antibodies were added for 30 min on ice. 
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Finally, the cells were washed three times and re-suspended in 1% para-formaldehyde. 
The stained samples were acquired with a FACS Calibur (BD Biosciences) and the data 
were analyzed using the FlowJo software. For corneas, total cell numbers were calculated 
by acquiring the totality of the sample and taking in consideration of the total number of 
corneas in the sample. To enumerate the number of IFN-" and IL-17 producing CD4
+
 T 
cells or IFN-" and TNF producing CD8
+
 T, cells were stimulated under appropriate 
conditions (PMA/IONO for CD4 T cells while gB or PMA/IONO for CD8 T cells) and 
intracellular cytokine staining was performed. 
Quantitative PCR (QPCR) and TaqMan QPCR: QPCR and Taqman miRNA QPCR 
was performed as previously described. The primers used for QPCR were as follows: IL-
1b, IFN-g, TNF, CXCL1, CCL2, CXCL10, CXCR3, CXCR4, MMP-9, IL-6, IL-12, IL-
10, TGFb and beta actin. TaqMan MicroRNA Assay (Applied Biosystems, USA) for 
miR-155 was used for quantification using a real-time PCR detection system and data 
were normalized to the internal control small nucleolar RNA 202.  
Viral plaque assay: Virus titers were measured in the brain, TG and eye swabs taken 
from HSV infected mice using plaque assays as described previously by others(Mulik, 
Xu et al. 2012). 
Statistics: The statistical significance for SK lesion severity and angiogenesis between 
two groups was determined using unpaired two-tailed student's t test. One way ANOVA 
with Bonferroni’s post hoc test was used to calculate the level of significance for some 
experiments. P ( 0.001 (***), P ( 0.01 (**), P ( 0.05 (*) were considered as significant 
and results are expressed as mean ±SEM. For all statistical analysis, GraphPad Prism 
software was used. 
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Results and Discussion 
miR-155 deficient mice die due to encephalitis after HSV-1 infection. miR-155 is an 
intensely studied miRNA which plays critical role in inflammation(Bhattacharyya, 
Balakathiresan et al. 2011), innate immunity and antibody production(Thai, Calado et al. 
2007; O'Neill, Sheedy et al. 2011). No reports have yet evaluated the role of miRNAs in 
regulation of HSE. We studied this using miR-155 deficient mouse on a C57B/6 
background (miR-155KO). WT C57B/6 mice and miR-155KO animals were infected 
ocularly with HSV-1 and monitored for ocular disease and neurological signs. All WT 
mice were free from any neurological signs and resistant to HSE as observed 
previously(Lundberg, Welander et al. 2007). Surprisingly, 75-80% of the miR-155 
deficient mice developed encephalitis and died by day 9 post infection (figure 4.1A). 
When virus levels in brain were measured in both groups at day 9 p.i. WT mice were 
negative for HSV by plaque assay while all miR-155 deficient mice had very high titers 
of virus in the brain (figure 4.1B). However, virus was cleared efficiently from corneas 
and trigeminal ganglia in miR-155 null mice similar to results in WT animals (figure 
4.2A-B). Overall, these results indicate that mice with a deficiency of miR-155 are highly 
susceptible to HSE. 
Virus replication in brain as a cause of death in miR-155 deficient mice. A series of 
publications by Casanova and Zheng et al demonstrate that mutations in TLR-3-IFN axis 
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are strongly associated with HSE thus supporting the role of uncontrolled virus 
replication as a cause of HSE(Zhang, Jouanguy et al. 2007; Pérez de Diego, Sancho-
Shimizu et al. 2010; Guo, Audry et al. 2011; Sancho-Shimizu, Pérez de Diego et al. 2011; 
Herman, Ciancanelli et al. 2012; Lafaille, Pessach et al. 2012; Reinert, Harder et al. 
2012). However, this issue remains debatable in mice with several reports showing 
inflammation as a trigger of HSE and death(Kurt-Jones, Chan et al. 2004; Mansur, Kroon 
et al. 2005; Wang, Bowen et al. 2012). We performed experiments in miR-155 deficient 
mice to determine the exact cause of death (virus replication versus inflammation). HSV 
after corneal infection enters brain by day 2-day 4 post infection(Shimeld, Efstathiou et 
al. 2001). Similarly, we could detect virus in the brain of HSV infected miR-155 deficient 
mice by day 3 post infection (figure 4.1C). Previous reports in mice show that even 
though virus replication is inhibited in brain via administration of acyclovir, a day after 
viral entry into brain, mice succumb to deadly encephalitis. This was explained by the 
initiation of an inflammatory response by HSV in brain, which resulted in severe damage. 
In those models, when the inflammatory responses were inhibited by neutrophil or 
macrophage depletion studies, mice were protected from HSE. Surprisingly, when we 
administered acyclovir to HSV infected miR-155 deficient mice  (from day 4 p.i.), the 
majority (80%) of mice were protected from encephalitis and this acyclovir treatment 
significantly lowered brain viral titers in miR-155KO mice (figure 4.1D-E). In summary, 
these results indicate that viral replication in the brain is the cause of encephalitis in miR-
155 null mice. Other groups have shown that TLR-2 mediated induction of inflammatory 
cytokines by microglia is a major reason for death in HSE in mice. In our experiments, 
miR-155 deficient microglia produced equivalent or in some cases even lesser amounts of 
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inflammatory molecules, which also disfavors inflammation as a cause of encephalitis in 
our case (figure 4.3A-L). Furthermore, experiments were performed to see whether 
astrocytes from miR-155 null mice were more susceptible to HSV-1 as recently observed 
by Paludan group with TLR-3 deficiency. Our results show that astrocytes isolated from 
miR-155 deficient mice are slightly more susceptible to HSV-1 infection than their WT 
counterparts but differences were not significant (data not shown). In additional 
experiments, brain IFNb levels were evaluated in WT and miR-155KO animals at 
different time points after infection. Interestingly, IFNb levels were slightly higher in 
miR-155 null animals at all the time points tested (figure 4.2C) suggesting no global 
defect in IFNb production in miR-155 deficient animals. 
Impaired CD4 and CD8 T cell responses in miR-155 null mice after HSV-1 
infection. miR-155 deficient mice demonstrate defects in the CD4 T cell and B cell 
responses(Rodriguez, Vigorito et al. 2007; O'Connell, Kahn et al. 2010; Murugaiyan, 
Beynon et al. 2011). Since CD4 and CD8 T cells are required to control HSV replication 
in brain, experiments were carried out to measure the magnitude of T cell responses in 
WT and miR-155 deficient mice infected with HSV. Recent report by the Paludan group 
showed that even though TLR-3 null mice succumbed to HSV-2 mediated encephalitis, 
those mice demonstrated equivalent CD4 and CD8 T cell responses to those of WT 
mice(Reinert, Harder et al. 2012). We infected WT and miR-155KO mice and studied T 
cell responses at day 9 p.i. In line with previous reports, miR-155 deficient mice 
produced fewer CD4 T cells making IFNg in LN and spleen (figure 4.4A-D, G-J). The 
lesser numbers of CD4 T cells producing IL-17A was also evident in LNs and spleens 
taken from miR-155KO mice (data not shown). Also in accord with recent 
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reports(Kohlhaas, Garden et al. 2009), miR-155 null mice revealed lesser Treg numbers 
in LN and spleen than WT animals(Liston, Lu et al. 2008; Lu, Thai et al. 2009) (figure 
4.4E-F, K-L). When CD8 T cell responses were analyzed, miR-155 deficient mice 
generated lesser total CD8 T cells and virus specific (gB tetramer specific) CD8 T cell 
responses (figure 4.5 and figure 4.6). When CD8 T cells from LN or spleen were 
stimulated with gB (immunodominat epitope of HSV), miR-155 deficient animals 
showed significantly fewer IFNg producing or IFNg and TNFa secreting CD8 T cells 
compared to WT animals (figure 4.6A-L). This was also evident after non specific 
stimulation of CD8 T cells (PMA/Ionomycin). As in this case, miR-155 deficient mice 
produced lesser IFNg or IFNg and TNFa secreting CD8 T cells in LN and spleen (figure 
4.5A-L). In conclusion, these results support viral replication as the cause of encephalitis 
in miR-155 deficient mice and such defect in viral clearance could be due to 
compromised CD4 and CD8 T cell responses in peripheral lymphoid organs. 
miR-155 deficiency leads to attenuated SK lesions and demonstrate diminished Th1 
responses. Mice infected ocularly with HSV develop ocular 
immunopathology(Niemialtowski and Rouse 1992). We did these experiments to see 
whether miR-155 deficient mice differ in susceptibility to SK. Recent reports show that 
miR-155KO mice are resistant to multiple sclerosis and rheumatoid arthritis 
models(O'Connell, Kahn et al. 2010; Blüml, Bonelli et al. 2011). All WT mice infected 
with HSV developed SK but miR-155 KO survivors from encephalitis were relatively 
resistant to SK and revealed significantly lower SK lesion scores and the extent of 
angiogenesis (figure 4.7A-D). Recently, Baltimore group demonstrated that miR-155 KO 
animals generate significantly lower pathogenic Th1 and Th-17 cells(O'Connell, Kahn et 
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al. 2010). In line with these reports, HSV infected miR-155 deficient mice produced 
fewer Th1 cells in LN, spleen and corneas (figure 4.8A-I). In another set of experiments, 
we locally knocked down miR-155 using antagomir-155 nanoparticles in eyes of WT 
mice. This treatment modality did not increase susceptibility of those mice to encephalitis 
after HSV infection but resulted in significant reduction in ocular immunopathology, led 
to a potent reduction in inflammatory and angiogenic molecules in eyes (figure 4.7E-
J)(Bhattacharyya, Balakathiresan et al. 2011). Interestingly, silencing of both miR-155 
and miR-132 (angiogenic)(Zheng, Schwarz et al. 2001; Anand, Majeti et al. 2010; Mulik, 
Xu et al. 2012) led to potent reduction in severity of SK and an extent of angiogenesis 
(figure 4.7) meaning combinatorial blockade(Kim, Tang et al. 2004) of both miRNAs 
could have translational potential to treat SK. 
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 Appendix 
 
Figure 4.1. miR-155 null mice are very susceptible to HSV-1 encephalitis. A) WT and 
miR-155 deficient mice were ocularly infected with HSV and monitored for the 
development of encephalitis and death. B) Brian viral titers in WT and miR-155 null 
mice at day 9 p.i. C) Brain histopathology performed at day 9 p.i. D) WT and miR-
155KO mice were infected with HSV and given acyclovir as shown and monitored for 
the mortality. E) Brain viral titers in WT, miR-155 deficient mice and acyclovir treated 
animals at day 9 p.i. These experiments were repeated three times. 
0
20000
40000
60000
80000
120000
P
F
U
/b
r
a
in
*** 
 
 
WT  
0 1 2 3 4 5 6 7 8 9
0
20
40
60
80
100
WT
miR155 KO
days post-infection
%
 o
f 
s
u
r
v
iv
a
l
!!!
KO  
A B
                                0                                  4              5              6           7         8      9 days p.i. 
HSV infection  
Acyclovir (1 mg)/vehicle 
   !
Analysis and  
collection of 
brains 
* 
 
 
* 
 
 
WT  KO KO Acyclovir 
0
100000
200000
300000
P
F
U
/b
ra
in
WT Acyclovir  
0 1 2 3 4 5 6 7 8 9
0
20
40
60
80
100
WT
WT acyclovir
days post-infection
%
 o
f s
ur
vi
va
l
miR155 KO
miR155 KO acyclovir
!!
0
500
1000
P
F
U
/b
ra
in
       
* 
 
WT  
D1  
WT  
D2  
WT  
D3 
WT  
D4  
KO 
D1  
KO 
D2  
KO 
D3  
KO 
D4  
C D 
E 
F 
 %7%"
"
 
Figure 4.2. Ocular and TG viral clearance from WT and KO animals. A) WT and 
miR-155 deficient mice were ocularly infected with HSV and eye swabs were collected 
for virus quantification. Virus levels are shown. B) TG viral titers in WT and miR-155 
null mice at day 2, 3 and day 8 p.i. C) Brainstem IFNb levels at various time points post 
infection are shown. 
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Figure 4.3. Microglial response from WT and KO animals. A-L) WT and miR-155 
deficient microglia were purified and stimulated with TLR-2 ligand, TLR-4 ligand and 
HSV and various molecules were quantified at 6 hours p.i. 
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Figure 4.4. Compromised CD4 T cell responses in miR-155 deficient mice. DLN cells 
and splenocytes were stimulated with PMA/IONO for 4 hrs and ICCS was performed. A, 
B) The frequencies and total numbers of total CD4 T cells in DLN in WT and miR-
155KO mice. The frequencies and total numbers of IFNg+ (C, D) and FoxP3+ (E,F) CD4 
T cells in DLN. (G, H) The frequencies and total numbers of total CD4 T cells in spleen 
in WT and miR-155KO mice. The frequencies and total numbers of IFNg+ (C, D) and 
FoxP3+ (E,F) CD4 T cells in spleen. These experiments were repeated three times. 
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Figure 4.5. Compromised CD8 T cell responses in miR-155 deficient mice. DLN cells 
and splenocytes were stimulated with PMA/IONO for 4 hrs and ICCS was performed. A, 
B) The frequencies and total numbers of CD8 T cells in DLN in WT and miR-155KO 
mice. The frequencies and total numbers of IFNg+ (C, D), TNF+ (C, E), IFN-g and 
TNF+ (C, F) CD8 T cells in DLN. G, H) The frequencies and total numbers of CD8 T 
cells in spleen in WT and miR-155KO mice. The frequencies and total numbers of IFNg+ 
(I, J), TNF+ (I, K), IFN-g and TNF+ (I, L) CD8 T cells in spleen. These experiments 
were repeated three times. 
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Figure 4.6. Compromised virus specific CD8 T cell responses in miR-155 deficient 
mice. DLN cells and splenocytes were stimulated with gB for 6 hrs and ICCS was 
performed. A, B) The frequencies and total numbers of gB tetramer+ CD8 T cells in 
DLN in WT and miR-155KO mice. The frequencies and total numbers of IFNg+ (C, D), 
TNF+ (C, E), IFN-g and TNF+ (C, F) CD8 T cells in DLN. G, H) The frequencies and 
total numbers of gB tetramer+ CD8 T cells in spleen in WT and miR-155KO mice. The 
frequencies and total numbers of IFNg+ (I, J), TNF+ (I, K), IFN-g and TNF+ (I, L) CD8 
T cells in spleen. These experiments were repeated three times. 
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Figure 4.7. miR-155 deficiency makes mice resistant to SK. A-D) WT and miR-155 
deficient mice were ocularly infected with HSV and monitored for the development of 
SK and angiogenesis. These experiments were repeated three times. SK and angiogenesis 
scores (A-D) after knockdown of miR-155 or miR-155 and miR-132 at day 12 and day 
15 p.i. QPCR was performed to measure levels of MMP-9 (E), IL-6 (F), IL-1b (G), KC 
(H) and MCP (I) after miR-155 silencing. J) WB images for VEGF, MMP-2 and MMP-9 
after miR-155 knockdown are shown."
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Figure 4.8. miR-155KO animals demonstrate diminished Th-1 responses. A-H) WT 
and miR-155 deficient mice were ocularly infected with HSV and LN, spleen and corneas 
were analyzed for Th1 cells by ICCS assay. Representative frequency plots; frequencies 
and total numbers of Th1 cells in LN (A-C), spleen (D-F) and corneas (G-I) are shown. 
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Conclusions and future perspectives 
 
Herpes simplex virus infection generally leads to lesions on oral surface. In rare 
instances, virus can induce damage of the eyes (herpetic stromal keratitis) or brain 
(herpes simplex encephalitis). HSK remains the leading cause of infectious blindness in 
the western world and the current therapies are unsatisfactory. Corneal 
neovascularization is a critical step in the pathogenesis of HSK and studies using mouse 
models demonstrate that inhibition of corneal blood vessel development may halt disease 
progression. Our past studies have firmly established an essential role of VEGF in CV 
and therapies that remove the source of VEGF, or inhibit VEGF activity or VEGF 
signaling have shown promise in treating HSK in mouse models. 
Our first approach to inhibit CV was augmentation of regulatory pathways. We 
chose Slit2-Robo4 signaling as it was shown to play a modulatory role in cancer models. 
After virus infection, we found upregulation of Robo4 but Slit2 expression was 
diminished. Additionally, our results demonstrate that potentiation of Robo4 signaling by 
administration of Slit2 significantly reduced CV. We plan to extend our observations and 
look in depth at molecular mechanisms to determine why Slit2 induction is inhibited in 
eyes after HSV infection. In this aspect, we will look at the expression of several 
microRNAs targeting Slit2 in eyes. We will also perform experiments in vitro in a 
corneal cell line and in vivo in mice by addition of certain cytokines or using cytokine-
neutralizing antibodies to evaluate Slit2 expression. We intend to administer Slit2 in 
nanoparticles to HSV infected mice. Additionally, we plan to use Arf6 or Rac1 inhibitor 
(which will mimic Slit2-Robo4 signaling) and will study the expression of HSK after 
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such treatment modalities. Optimistically, potentiation of Slit2-Robo4 signaling may help 
to reduce human SK. 
Our other attempts to reduce HSK involved manipulation of microRNAs, which 
have been recently shown to play a role in several human diseases. miRNAs are post 
transcriptional regulators of gene expression and they do it so by promoting degradation 
of mRNA or inhibition of protein translation. miRNA blockade offers new opportunities 
to halt the progression of human diseases. We focused on miR-132 and miR-155 since 
these miRNAs play a pivotal role in angiogenesis and inflammation respectively. 
miR-132 is one of the highly conserved miRNA and its function depends on the 
context where it is expressed. Accordingly, miR-132 induced neuronal differentiation in 
brain, performed anti-inflammatory action at neural immune interface, and promoted 
IFNs in KSHV infected lymphatic endothelial cells while it induced an angiogenic switch 
in cancer. Our results show that miR-132 expression is upregulated in corneas and it 
enhanced VEGF signaling during HSK. Inhibition of miR-132 significantly reduced CV. 
We plan to perform future experiments in miR-132 deficient mice, which we believe 
could be relatively resistant to CV. We intend to investigate miR-132 targets in depth in 
collaboration using various 3’UTR gene mutated plasmids. We also plan to investigate 
development of lymphatic vessels in corneas of miR-132 deficient mice after HSV 
infection. Additionally, we will block the activity of other angiogenic or tissue damaging 
molecules in miR-132 deficient mice and will look at the expression of HSK. 
Furthermore, we will also attempt to design slow drug release antagomir-132 
nanoparticles that could be given topically to the eyes. We hope that miR-132 blockade 
approaches will someday be useful for human HSK therapy. 
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miR-155 is one of the intensely studied miRNA and it is required for normal 
immune function. Recent reports suggest that miR-155 is tightly linked with the 
inflammatory processes and is needed for the generation of pathogenic Th1 and Th17 
cells. Consequently, mice deficient in miR-155 are resistant to some inflammatory and 
autoimmune diseases such as EAE and RA. We observed induction of miR-155 in eyes 
after herpes infection. Surprisingly, after infection with HSV, 80% miR-155KO mice 
died by encephalitis due to uncontrolled virus replication and those miR-155 deficient 
mice demonstrated a defect in CD8 T cells as well as other immune cells. We also 
studied miR-155KO survivors and those animals were relatively resistant to HSK. This 
phenotype was also evident after local knockdown of miR-155 in eyes. Finally, when 
miR-132 and miR-155 were inhibited together, this treatment modality potently reduced 
CV and HSK lesion severity. Future experiments will be performed to investigate the 
CD8 T cell defect in miR-155 KO mice as well as study of the miR-155 targets after local 
miR-155 silencing. 
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